











Mon Feb 11 09:19:43 2002

us-10-006-430-51.szlm60.rge

Page 6









[illegible][illegible]

ACCESSION: GenBank/GenBank  
 ID: U00001.1  
 NAME: BAC1.1  
 DEFINITION: BAC1.1

GenBank Match: 64,000; Score: 12.8; 100%; Length: 192  
 GenBank ID: U00001.1; Accession: U00001.1; Date: 1990-04-04  
 Match: 14; Conserved: 0; Mismatch: 2; Indels: 0; Gaps: 0

GenBank ID: U00001.1  
 Accession: U00001.1  
 Name: BAC1.1  
 Definition: BAC1.1  
 Accession: U00001.1  
 Date: 1990-04-04  
 Match: 14; Conserved: 0; Mismatch: 2; Indels: 0; Gaps: 0

GenBank ID: U00001.1  
 Accession: U00001.1  
 Name: BAC1.1  
 Definition: BAC1.1  
 Accession: U00001.1  
 Date: 1990-04-04  
 Match: 14; Conserved: 0; Mismatch: 2; Indels: 0; Gaps: 0

GenBank ID: U00001.1  
 Accession: U00001.1  
 Name: BAC1.1  
 Definition: BAC1.1  
 Accession: U00001.1  
 Date: 1990-04-04  
 Match: 14; Conserved: 0; Mismatch: 2; Indels: 0; Gaps: 0

GenBank ID: U00001.1  
 Accession: U00001.1  
 Name: BAC1.1  
 Definition: BAC1.1  
 Accession: U00001.1  
 Date: 1990-04-04  
 Match: 14; Conserved: 0; Mismatch: 2; Indels: 0; Gaps: 0

GenBank ID: U00001.1  
 Accession: U00001.1  
 Name: BAC1.1  
 Definition: BAC1.1  
 Accession: U00001.1  
 Date: 1990-04-04  
 Match: 14; Conserved: 0; Mismatch: 2; Indels: 0; Gaps: 0

GenBank ID: U00001.1  
 Accession: U00001.1  
 Name: BAC1.1  
 Definition: BAC1.1  
 Accession: U00001.1  
 Date: 1990-04-04  
 Match: 14; Conserved: 0; Mismatch: 2; Indels: 0; Gaps: 0

GenBank ID: U00001.1  
 Accession: U00001.1  
 Name: BAC1.1  
 Definition: BAC1.1  
 Accession: U00001.1  
 Date: 1990-04-04  
 Match: 14; Conserved: 0; Mismatch: 2; Indels: 0; Gaps: 0





[illegible][illegible][illegible][illegible]

1. *Chlorophyll a* and *Chlorophyll b* were determined using a spectrophotometer (Shimadzu UV-1601) at 663 nm and 646 nm, respectively. The concentrations were calculated using the following equations:  $\text{Chlorophyll } a = 12.7 \times \text{Absorbance at } 663 \text{ nm}$  and  $\text{Chlorophyll } b = 22.9 \times \text{Absorbance at } 646 \text{ nm}$ .

[illegible][illegible]

Handwritten signature: *[Signature]*

Variable	Unit	Value
1. $\alpha$	1	0.001
2. $\beta$	1	0.001
3. $\gamma$	1	0.001
4. $\delta$	1	0.001
5. $\epsilon$	1	0.001
6. $\zeta$	1	0.001
7. $\eta$	1	0.001
8. $\theta$	1	0.001
9. $\iota$	1	0.001
10. $\kappa$	1	0.001
11. $\lambda$	1	0.001
12. $\mu$	1	0.001
13. $\nu$	1	0.001
14. $\xi$	1	0.001
15. $\omicron$	1	0.001
16. $\pi$	1	0.001
17. $\rho$	1	0.001
18. $\sigma$	1	0.001
19. $\tau$	1	0.001
20. $\upsilon$	1	0.001
21. $\phi$	1	0.001
22. $\chi$	1	0.001
23. $\psi$	1	0.001
24. $\omega$	1	0.001
25. $\delta$	1	0.001
26. $\epsilon$	1	0.001
27. $\zeta$	1	0.001
28. $\eta$	1	0.001
29. $\theta$	1	0.001
30. $\iota$	1	0.001
31. $\kappa$	1	0.001
32. $\lambda$	1	0.001
33. $\mu$	1	0.001
34. $\nu$	1	0.001
35. $\xi$	1	0.001
36. $\omicron$	1	0.001
37. $\pi$	1	0.001
38. $\rho$	1	0.001
39. $\sigma$	1	0.001
40. $\tau$	1	0.001
41. $\upsilon$	1	0.001
42. $\phi$	1	0.001
43. $\chi$	1	0.001
44. $\psi$	1	0.001
45. $\omega$	1	0.001
46. $\delta$	1	0.001
47. $\epsilon$	1	0.001
48. $\zeta$	1	0.001
49. $\eta$	1	0.001
50. $\theta$	1	0.001
51. $\iota$	1	0.001
52. $\kappa$	1	0.001
53. $\lambda$	1	0.001
54. $\mu$	1	0.001
55. $\nu$	1	0.001
56. $\xi$	1	0.001
57. $\omicron$	1	0.001
58. $\pi$	1	0.001
59. $\rho$	1	0.001
60. $\sigma$	1	0.001
61. $\tau$	1	0.001
62. $\upsilon$	1	0.001
63. $\phi$	1	0.001
64. $\chi$	1	0.001
65. $\psi$	1	0.001
66. $\omega$	1	0.001
67. $\delta$	1	0.001
68. $\epsilon$	1	0.001
69. $\zeta$	1	0.001
70. $\eta$	1	0.001
71. $\theta$	1	0.001
72. $\iota$	1	0.001
73. $\kappa$	1	0.001
74. $\lambda$	1	0.001
75. $\mu$	1	0.001
76. $\nu$	1	0.001
77. $\xi$	1	0.001
78. $\omicron$	1	0.001
79. $\pi$	1	0.001
80. $\rho$	1	0.001
81. $\sigma$	1	0.001
82. $\tau$	1	0.001
83. $\upsilon$	1	0.001
84. $\phi$	1	0.001
85. $\chi$	1	0.001
86. $\psi$	1	0.001
87. $\omega$	1	0.001
88. $\delta$	1	0.001
89. $\epsilon$	1	0.001
90. $\zeta$	1	0.001
91. $\eta$	1	0.001
92. $\theta$	1	0.001
93. $\iota$	1	0.001
94. $\kappa$	1	0.001
95. $\lambda$	1	0.001
96. $\mu$	1	0.001
97. $\nu$	1	0.001
98. $\xi$	1	0.001
99. $\omicron$	1	0.001
100. $\pi$	1	0.001

REPORTING TO THE EDITOR: I have read with interest the article by Dr. A. C. Woolley, H. H. Johnson, and J. E. Johnson, "The Effect of Age and Sex on the Incidence of Cervical Intraepithelial Neoplasia (CIN) and Cervical Squamous Metaplasia (CSM) in the Cervix," published in the November 1987 issue of the *Journal of the American Academy of Child and Adolescent Psychiatry*. The authors conclude that the incidence of CIN and CSM is higher in older women than in younger women, and that the incidence is higher in women with a history of sexual abuse than in women without a history of sexual abuse. The authors also conclude that the incidence of CIN and CSM is higher in women with a history of sexual abuse than in women without a history of sexual abuse. The authors also conclude that the incidence of CIN and CSM is higher in women with a history of sexual abuse than in women without a history of sexual abuse.

[illegible]

ARTIST:IN	Artist:open
VERSION	Album:version:1
KEYWORDS	Album:keywords:1
Source:	Album:source
copyright:	Album:copyright

[illegible]

1. The first group of authors (e.g., [1, 2]) has shown that the use of a single, common, non-physical, reference frame for all the particles in the system is not only unphysical, but also leads to a violation of the principle of relativity. This is because the laws of physics are not the same in all reference frames. The laws of physics are only the same in reference frames that are moving with a constant velocity relative to each other. This is the principle of relativity. The use of a single, common, non-physical, reference frame for all the particles in the system is not only unphysical, but also leads to a violation of the principle of relativity. This is because the laws of physics are not the same in all reference frames. The laws of physics are only the same in reference frames that are moving with a constant velocity relative to each other. This is the principle of relativity.

Abundance	Mass	Formula	Calculated	Found
100	141	$C_9H_9$	141.0686	141.0686
100	155	$C_9H_9NO$	155.0639	155.0639
100	169	$C_9H_9N_2$	169.0690	169.0690
100	183	$C_9H_9N_2O$	183.0642	183.0642
100	197	$C_9H_9N_2O_2$	197.0693	197.0693
100	211	$C_9H_9N_3$	211.0744	211.0744
100	225	$C_9H_9N_3O$	225.0696	225.0696
100	239	$C_9H_9N_3O_2$	239.0747	239.0747
100	253	$C_9H_9N_3O_3$	253.0798	253.0798
100	267	$C_9H_9N_4$	267.0849	267.0849
100	281	$C_9H_9N_4O$	281.0800	281.0800
100	295	$C_9H_9N_4O_2$	295.0851	295.0851
100	309	$C_9H_9N_4O_3$	309.0902	309.0902
100	323	$C_9H_9N_4O_4$	323.0953	323.0953
100	337	$C_9H_9N_5$	337.0904	337.0904
100	351	$C_9H_9N_5O$	351.0855	351.0855
100	365	$C_9H_9N_5O_2$	365.0906	365.0906
100	379	$C_9H_9N_5O_3$	379.0957	379.0957
100	393	$C_9H_9N_5O_4$	393.1008	393.1008
100	407	$C_9H_9N_6$	407.0959	407.0959
100	421	$C_9H_9N_6O$	421.0910	421.0910
100	435	$C_9H_9N_6O_2$	435.0961	435.0961
100	449	$C_9H_9N_6O_3$	449.1012	449.1012
100	463	$C_9H_9N_6O_4$	463.1063	463.1063
100	477	$C_9H_9N_7$	477.1014	477.1014
100	491	$C_9H_9N_7O$	491.0965	491.0965
100	505	$C_9H_9N_7O_2$	505.1016	505.1016
100	519	$C_9H_9N_7O_3$	519.1067	519.1067
100	533	$C_9H_9N_7O_4$	533.1118	533.1118
100	547	$C_9H_9N_8$	547.1069	547.1069
100	561	$C_9H_9N_8O$	561.1020	561.1020
100	575	$C_9H_9N_8O_2$	575.1071	575.1071
100	589	$C_9H_9N_8O_3$	589.1122	589.1122
100	603	$C_9H_9N_8O_4$	603.1173	603.1173
100	617	$C_9H_9N_9$	617.1124	617.1124
100	631	$C_9H_9N_9O$	631.1075	631.1075
100	645	$C_9H_9N_9O_2$	645.1126	645.1126
100	659	$C_9H_9N_9O_3$	659.1177	659.1177
100	673	$C_9H_9N_{10}$	673.1128	673.1128
100	687	$C_9H_9N_{10}O$	687.1079	687.1079
100	701	$C_9H_9N_{10}O_2$	701.1130	701.1130
100	715	$C_9H_9N_{10}O_3$	715.1181	715.1181
100	729	$C_9H_9N_{11}$	729.1132	729.1132
100	743	$C_9H_9N_{11}O$	743.1083	743.1083
100	757	$C_9H_9N_{11}O_2$	757.1134	757.1134
100	771	$C_9H_9N_{11}O_3$	771.1185	771.1185
100	785	$C_9H_9N_{12}$	785.1136	785.1136
100	799	$C_9H_9N_{12}O$	799.1087	799.1087
100	813	$C_9H_9N_{12}O_2$	813.1138	813.1138
100	827	$C_9H_9N_{12}O_3$	827.1189	827.1189
100	841	$C_9H_9N_{13}$	841.1140	841.1140
100	855	$C_9H_9N_{13}O$	855.1091	855.1091
100	869	$C_9H_9N_{13}O_2$	869.1142	869.1142
100	883	$C_9H_9N_{13}O_3$	883.1193	883.1193
100	897	$C_9H_9N_{14}$	897.1144	897.1144
100				

RECEIVED  
AT THE  
OFFICE OF THE  
CLERK OF THE  
SUPREME COURT  
JAN 10 1901

[illegible]

REFERENCE	ALPHABET	LINE	FEATURES	SOURCE
2 (bases 1 to 51)	ACCTGTC	1	1	1
3 (bases 1 to 51)	ACCTGTC	1	1	1
4 (bases 1 to 51)	ACCTGTC	1	1	1
5 (bases 1 to 51)	ACCTGTC	1	1	1
6 (bases 1 to 51)	ACCTGTC	1	1	1
7 (bases 1 to 51)	ACCTGTC	1	1	1
8 (bases 1 to 51)	ACCTGTC	1	1	1
9 (bases 1 to 51)	ACCTGTC	1	1	1
10 (bases 1 to 51)	ACCTGTC	1	1	1
11 (bases 1 to 51)	ACCTGTC	1	1	1
12 (bases 1 to 51)	ACCTGTC	1	1	1
13 (bases 1 to 51)	ACCTGTC	1	1	1
14 (bases 1 to 51)	ACCTGTC	1	1	1
15 (bases 1 to 51)	ACCTGTC	1	1	1
16 (bases 1 to 51)	ACCTGTC	1	1	1
17 (bases 1 to 51)	ACCTGTC	1	1	1
18 (bases 1 to 51)	ACCTGTC	1	1	1
19 (bases 1 to 51)	ACCTGTC	1	1	1
20 (bases 1 to 51)	ACCTGTC	1	1	1
21 (bases 1 to 51)	ACCTGTC	1	1	1
22 (bases 1 to 51)	ACCTGTC	1	1	1
23 (bases 1 to 51)	ACCTGTC	1	1	1
24 (bases 1 to 51)	ACCTGTC	1	1	1
25 (bases 1 to 51)	ACCTGTC	1	1	1
26 (bases 1 to 51)	ACCTGTC	1	1	1
27 (bases 1 to 51)	ACCTGTC	1	1	1
28 (bases 1 to 51)	ACCTGTC	1	1	1
29 (bases 1 to 51)	ACCTGTC	1	1	1
30 (bases 1 to 51)	ACCTGTC	1	1	1
31 (bases 1 to 51)	ACCTGTC	1	1	1
32 (bases 1 to 51)	ACCTGTC	1	1	1
33 (bases 1 to 51)	ACCTGTC	1	1	1
34 (bases 1 to 51)	ACCTGTC	1	1	1
35 (bases 1 to 51)	ACCTGTC	1	1	1
36 (bases 1 to 51)	ACCTGTC	1	1	1
37 (bases 1 to 51)	ACCTGTC	1	1	1
38 (bases 1 to 51)	ACCTGTC	1	1	1
39 (bases 1 to 51)	ACCTGTC	1	1	1
40 (bases 1 to 51)	ACCTGTC	1	1	1
41 (bases 1 to 51)	ACCTGTC	1	1	1
42 (bases 1 to 51)	ACCTGTC	1	1	1
43 (bases 1 to 51)	ACCTGTC	1	1	1
44 (bases 1 to 51)	ACCTGTC	1	1	1
45 (bases 1 to 51)	ACCTGTC	1	1	1
46 (bases 1 to 51)	ACCTGTC	1	1	1
47 (bases 1 to 51)	ACCTGTC	1	1	1
48 (bases 1 to 51)	ACCTGTC	1	1	1
49 (bases 1 to 51)	ACCTGTC	1	1	1
50 (bases 1 to 51)	ACCTGTC	1	1	1
51 (bases 1 to 51)	ACCTGTC	1	1	1







Mon Feb 11 09:19:46 2002

us-10-006-430-54.szlm60.rge

Page 6



Contract/Grant No.: CO-56000; CO; NCI  
Document type: Journal Article  
Languages: ENGLISH  
Main Citation Owner: NLM  
Record type: Completed

The envelope proteins of hepatitis C virus (HCV) are the likely targets of neutralizing **antibodies** and their molecular and functional characterization is relevant for vaccine development. We previously showed that surface-expressed E2 is a better immunogen than intracellular E2 and, therefore, we were interested in exploring more efficient ways to present E2 protein on the cell surface. We found that E2 targeted to the cell surface by replacement of its transmembrane domain did not bring E1 to the surface although E1 could be expressed independently on the cell surface if its transmembrane domain was similarly replaced. FACS analysis suggested that E2 expressed on the cell surface acquired its native conformation more efficiently when truncated at aa 661 than when truncated at aa 715. The shorter form of truncated E2 better retained the ability to bind the second extracellular loop (EC2) of CD81, the putative HCV receptor. Interestingly, deletion of the hypervariable region 1 (HVR1) did not perceptibly alter E2 structure; cell-surface forms of E2 lacking the HVR1 remained reactive with conformation-sensitive MAbs and were able to bind recombinant EC2 of CD81.

Copyright 2000 Academic Press.

4/3,AB/20 (Item 20 from file: 155)  
DIALOG(R)File 155:MEDLINE(R)

10823838 20363096 PMID: 10907850

Sequence-based structural features between Kvlqt1 and Tapal on mouse

on human 11p15.5: long-stretches of unusually


of kvlqt1 between mouse and human

Department of Biochemistry, Saga Medical School, 1-1-1, Honjo-cho, Saga City, Saga Prefecture, Japan



[illegible]







Mon Feb 11 09:19:50 2002

us-10-006-430-61.s2lm60.rge

Page 1

Copyright 1994-2000 Compuserve, Inc.

Mon Feb 11 09:19:50 2002

Copyright 1994-2000 Compuserve, Inc.

Copyright 1994-2000 Compuserve, Inc.

Copyright 1994-2000 Compuserve, Inc.

Copyright 1994-2000 Compuserve, Inc.

Copyright 1994-2000 Compuserve, Inc.

Copyright 1994-2000 Compuserve, Inc.

Copyright 1994-2000 Compuserve, Inc.

Copyright 1994-2000 Compuserve, Inc.

Copyright 1994-2000 Compuserve, Inc.

Copyright 1994-2000 Compuserve, Inc.

Copyright 1994-2000 Compuserve, Inc.

Copyright 1994-2000 Compuserve, Inc.

Copyright 1994-2000 Compuserve, Inc.

Copyright 1994-2000 Compuserve, Inc.

Copyright 1994-2000 Compuserve, Inc.

Copyright 1994-2000 Compuserve, Inc.

Copyright 1994-2000 Compuserve, Inc.

Copyright 1994-2000 Compuserve, Inc.

Copyright 1994-2000 Compuserve, Inc.

Copyright 1994-2000 Compuserve, Inc.

Copyright 1994-2000 Compuserve, Inc.























Mon Feb 11 09:19:51 2002

us-10-006-430-63.szlm60.rge

Page 6



[illegible]

100

Case	Age	Sex	Site	Pathologic	Survival
1	65	M	Rectum	Adenocarcinoma	10 mo
2	68	M	Rectum	Adenocarcinoma	12 mo
3	70	M	Rectum	Adenocarcinoma	14 mo
4	72	M	Rectum	Adenocarcinoma	16 mo
5	75	M	Rectum	Adenocarcinoma	18 mo
6	78	M	Rectum	Adenocarcinoma	20 mo
7	80	M	Rectum	Adenocarcinoma	22 mo
8	82	M	Rectum	Adenocarcinoma	24 mo
9	85	M	Rectum	Adenocarcinoma	26 mo
10	88	M	Rectum	Adenocarcinoma	28 mo
11	90	M	Rectum	Adenocarcinoma	30 mo
12	92	M	Rectum	Adenocarcinoma	32 mo
13	95	M	Rectum	Adenocarcinoma	34 mo
14	98	M	Rectum	Adenocarcinoma	36 mo
15	100	M	Rectum	Adenocarcinoma	38 mo
16	102	M	Rectum	Adenocarcinoma	40 mo
17	105	M	Rectum	Adenocarcinoma	42 mo
18	108	M	Rectum	Adenocarcinoma	44 mo
19	110	M	Rectum	Adenocarcinoma	46 mo
20	112	M	Rectum	Adenocarcinoma	48 mo
21	115	M	Rectum	Adenocarcinoma	50 mo
22	118	M	Rectum	Adenocarcinoma	52 mo
23	120	M	Rectum	Adenocarcinoma	54 mo
24	122	M	Rectum	Adenocarcinoma	56 mo
25	125	M	Rectum	Adenocarcinoma	58 mo
26	128	M	Rectum	Adenocarcinoma	60 mo
27	130	M	Rectum	Adenocarcinoma	62 mo
28	132	M	Rectum	Adenocarcinoma	64 mo
29	135	M	Rectum	Adenocarcinoma	66 mo
30	138	M	Rectum	Adenocarcinoma	68 mo
31	140	M	Rectum	Adenocarcinoma	70 mo
32	142	M	Rectum	Adenocarcinoma	72 mo
33	145	M	Rectum	Adenocarcinoma	74 mo
34	148	M	Rectum	Adenocarcinoma	76 mo
35	150	M	Rectum	Adenocarcinoma	78 mo
36	152	M	Rectum	Adenocarcinoma	80 mo
37	155	M	Rectum	Adenocarcinoma	82 mo
38	158	M	Rectum	Adenocarcinoma	84 mo
39	160	M	Rectum	Adenocarcinoma	86 mo
40	162	M	Rectum	Adenocarcinoma	88 mo
41	165	M	Rectum	Adenocarcinoma	90 mo
42	168	M	Rectum	Adenocarcinoma	92 mo
43	170	M	Rectum	Adenocarcinoma	94 mo
44	172	M	Rectum	Adenocarcinoma	96 mo
45	175	M	Rectum	Adenocarcinoma	98 mo
46	178	M	Rectum	Adenocarcinoma	100 mo
47	180	M	Rectum	Adenocarcinoma	102 mo
48	182	M	Rectum	Adenocarcinoma	104 mo
49	185	M	Rectum	Adenocarcinoma	106 mo
50	188	M	Rectum	Adenocarcinoma	108 mo
51	190	M	Rectum	Adenocarcinoma	110 mo
52	192	M	Rectum	Adenocarcinoma	112 mo
53	195	M	Rectum	Adenocarcinoma	114 mo
54	198	M	Rectum	Adenocarcinoma	116 mo
55	200	M	Rectum	Adenocarcinoma	118 mo
56	202	M	Rectum	Adenocarcinoma	120 mo
57	205	M	Rectum	Adenocarcinoma	122 mo
58	208	M	Rectum	Adenocarcinoma	124 mo
59	210	M	Rectum	Adenocarcinoma	126 mo
60	212	M	Rectum	Adenocarcinoma	128 mo
61	215	M	Rectum	Adenocarcinoma	130 mo
62	218	M	Rectum	Adenocarcinoma	132 mo
63	220	M	Rectum	Adenocarcinoma	134 mo
64	222	M	Rectum	Adenocarcinoma	136 mo
65	225	M	Rectum	Adenocarcinoma	138 mo
66	228	M	Rectum	Adenocarcinoma	140 mo
67	230	M	Rectum	Adenocarcinoma	142 mo
68	232	M	Rectum	Adenocarcinoma	144 mo
69	235</				

[illegible][illegible]

# 2025-2026

[illegible][illegible][illegible][illegible]

4444 Forest Park Parkway, Box 9501, St. Louis, MO 63108  
 Tel: 314 296 1800  
 Fax: 314 296 1810  
 Email: [est@wustl.edu](mailto:est@wustl.edu)  
 This clone is available royalty free through JBM. For contact the  
 JBM Consortium (info: jbm-consortium.org) for further information.  
 Please consider overall poor quality.  
 Possible reversed clone similarity on wrong strand  
 See primer: [est@wustl.edu](mailto:est@wustl.edu)  
 High quality sequence stage: 1  
 Local copy/quality: 1

#### FEATURES

1. 43  
 2. 43  
 3. 43  
 4. 43  
 5. 43  
 6. 43  
 7. 43  
 8. 43  
 9. 43  
 10. 43  
 11. 43  
 12. 43  
 13. 43  
 14. 43  
 15. 43  
 16. 43  
 17. 43  
 18. 43  
 19. 43  
 20. 43  
 21. 43  
 22. 43  
 23. 43  
 24. 43  
 25. 43  
 26. 43  
 27. 43  
 28. 43  
 29. 43  
 30. 43  
 31. 43  
 32. 43  
 33. 43  
 34. 43  
 35. 43  
 36. 43  
 37. 43  
 38. 43  
 39. 43  
 40. 43  
 41. 43  
 42. 43  
 43. 43  
 44. 43  
 45. 43  
 46. 43  
 47. 43  
 48. 43  
 49. 43  
 50. 43  
 51. 43  
 52. 43  
 53. 43  
 54. 43  
 55. 43  
 56. 43  
 57. 43  
 58. 43  
 59. 43  
 60. 43  
 61. 43  
 62. 43  
 63. 43  
 64. 43  
 65. 43  
 66. 43  
 67. 43  
 68. 43  
 69. 43  
 70. 43  
 71. 43  
 72. 43  
 73. 43  
 74. 43  
 75. 43  
 76. 43  
 77. 43  
 78. 43  
 79. 43  
 80. 43  
 81. 43  
 82. 43  
 83. 43  
 84. 43  
 85. 43  
 86. 43  
 87. 43  
 88. 43  
 89. 43  
 90. 43  
 91. 43  
 92. 43  
 93. 43  
 94. 43  
 95. 43  
 96. 43  
 97. 43  
 98. 43  
 99. 43  
 100. 43

1. 43  
 2. 43  
 3. 43  
 4. 43  
 5. 43  
 6. 43  
 7. 43  
 8. 43  
 9. 43  
 10. 43  
 11. 43  
 12. 43  
 13. 43  
 14. 43  
 15. 43  
 16. 43  
 17. 43  
 18. 43  
 19. 43  
 20. 43  
 21. 43  
 22. 43  
 23. 43  
 24. 43  
 25. 43  
 26. 43  
 27. 43  
 28. 43  
 29. 43  
 30. 43  
 31. 43  
 32. 43  
 33. 43  
 34. 43  
 35. 43  
 36. 43  
 37. 43  
 38. 43  
 39. 43  
 40. 43  
 41. 43  
 42. 43  
 43. 43  
 44. 43  
 45. 43  
 46. 43  
 47. 43  
 48. 43  
 49. 43  
 50. 43  
 51. 43  
 52. 43  
 53. 43  
 54. 43  
 55. 43  
 56. 43  
 57. 43  
 58. 43  
 59. 43  
 60. 43  
 61. 43  
 62. 43  
 63. 43  
 64. 43  
 65. 43  
 66. 43  
 67. 43  
 68. 43  
 69. 43  
 70. 43  
 71. 43  
 72. 43  
 73. 43  
 74. 43  
 75. 43  
 76. 43  
 77. 43  
 78. 43  
 79. 43  
 80. 43  
 81. 43  
 82. 43  
 83. 43  
 84. 43  
 85. 43  
 86. 43  
 87. 43  
 88. 43  
 89. 43  
 90. 43  
 91. 43  
 92. 43  
 93. 43  
 94. 43  
 95. 43  
 96. 43  
 97. 43  
 98. 43  
 99. 43  
 100. 43

4444 Forest Park Parkway, Box 9501, St. Louis, MO 63108  
 Tel: 314 296 1800  
 Fax: 314 296 1810  
 Email: [est@wustl.edu](mailto:est@wustl.edu)  
 This clone is available royalty free through JBM. For contact the  
 JBM Consortium (info: jbm-consortium.org) for further information.  
 Please consider overall poor quality.  
 Possible reversed clone similarity on wrong strand  
 See primer: [est@wustl.edu](mailto:est@wustl.edu)  
 High quality sequence stage: 1  
 Local copy/quality: 1

#### FEATURES

1. 43  
 2. 43  
 3. 43  
 4. 43  
 5. 43  
 6. 43  
 7. 43  
 8. 43  
 9. 43  
 10. 43  
 11. 43  
 12. 43  
 13. 43  
 14. 43  
 15. 43  
 16. 43  
 17. 43  
 18. 43  
 19. 43  
 20. 43  
 21. 43  
 22. 43  
 23. 43  
 24. 43  
 25. 43  
 26. 43  
 27. 43  
 28. 43  
 29. 43  
 30. 43  
 31. 43  
 32. 43  
 33. 43  
 34. 43  
 35. 43  
 36. 43  
 37. 43  
 38. 43  
 39. 43  
 40. 43  
 41. 43  
 42. 43  
 43. 43  
 44. 43  
 45. 43  
 46. 43  
 47. 43  
 48. 43  
 49. 43  
 50. 43  
 51. 43  
 52. 43  
 53. 43  
 54. 43  
 55. 43  
 56. 43  
 57. 43  
 58. 43  
 59. 43  
 60. 43  
 61. 43  
 62. 43  
 63. 43  
 64. 43  
 65. 43  
 66. 43  
 67. 43  
 68. 43  
 69. 43  
 70. 43  
 71. 43  
 72. 43  
 73. 43  
 74. 43  
 75. 43  
 76. 43  
 77. 43  
 78. 43  
 79. 43  
 80. 43  
 81. 43  
 82. 43  
 83. 43  
 84. 43  
 85. 43  
 86. 43  
 87. 43  
 88. 43  
 89. 43  
 90. 43  
 91. 43  
 92. 43  
 93. 43  
 94. 43  
 95. 43  
 96. 43  
 97. 43  
 98. 43  
 99. 43  
 100. 43

1. 43  
 2. 43  
 3. 43  
 4. 43  
 5. 43  
 6. 43  
 7. 43  
 8. 43  
 9. 43  
 10. 43  
 11. 43  
 12. 43  
 13. 43  
 14. 43  
 15. 43  
 16. 43  
 17. 43  
 18. 43  
 19. 43  
 20. 43  
 21. 43  
 22. 43  
 23. 43  
 24. 43  
 25. 43  
 26. 43  
 27. 43  
 28. 43  
 29. 43  
 30. 43  
 31. 43  
 32. 43  
 33. 43  
 34. 43  
 35. 43  
 36. 43  
 37. 43  
 38. 43  
 39. 43  
 40. 43  
 41. 43  
 42. 43  
 43. 43  
 44. 43  
 45. 43  
 46. 43  
 47. 43  
 48. 43  
 49. 43  
 50. 43  
 51. 43  
 52. 43  
 53. 43  
 54. 43  
 55. 43  
 56. 43  
 57. 43  
 58. 43  
 59. 43  
 60. 43  
 61. 43  
 62. 43  
 63. 43  
 64. 43  
 65. 43  
 66. 43  
 67. 43  
 68. 43  
 69. 43  
 70. 43  
 71. 43  
 72. 43  
 73. 43  
 74. 43  
 75. 43  
 76. 43  
 77. 43  
 78. 43  
 79. 43  
 80. 43  
 81. 43  
 82. 43  
 83. 43  
 84. 43  
 85. 43  
 86. 43  
 87. 43  
 88. 43  
 89. 43  
 90. 43  
 91. 43  
 92. 43  
 93. 43  
 94. 43  
 95. 43  
 96. 43  
 97. 43  
 98. 43  
 99. 43  
 100. 43





and collected for anti-HIV resistance."

65.0% Score 12.0; 108.1% Length 427  
 best local similarity 100.0% Prod. No. 6,60043  
 Mismatch 1% Consensus 0% Mismatches 0% Indels 0% Gaps 0%

100.0% Score 12.0; 108.1% Length 427  
 best local similarity 100.0% Prod. No. 6,60043  
 Mismatch 1% Consensus 0% Mismatches 0% Indels 0% Gaps 0%

100.0% Score 12.0; 108.1% Length 427  
 best local similarity 100.0% Prod. No. 6,60043  
 Mismatch 1% Consensus 0% Mismatches 0% Indels 0% Gaps 0%

100.0% Score 12.0; 108.1% Length 427  
 best local similarity 100.0% Prod. No. 6,60043  
 Mismatch 1% Consensus 0% Mismatches 0% Indels 0% Gaps 0%

100.0% Score 12.0; 108.1% Length 427  
 best local similarity 100.0% Prod. No. 6,60043  
 Mismatch 1% Consensus 0% Mismatches 0% Indels 0% Gaps 0%

100.0% Score 12.0; 108.1% Length 427  
 best local similarity 100.0% Prod. No. 6,60043  
 Mismatch 1% Consensus 0% Mismatches 0% Indels 0% Gaps 0%

100.0% Score 12.0; 108.1% Length 427  
 best local similarity 100.0% Prod. No. 6,60043  
 Mismatch 1% Consensus 0% Mismatches 0% Indels 0% Gaps 0%

100.0% Score 12.0; 108.1% Length 427  
 best local similarity 100.0% Prod. No. 6,60043  
 Mismatch 1% Consensus 0% Mismatches 0% Indels 0% Gaps 0%

65.0% Score 12.0; 108.1% Length 427  
 best local similarity 100.0% Prod. No. 6,60043  
 Mismatch 1% Consensus 0% Mismatches 0% Indels 0% Gaps 0%

100.0% Score 12.0; 108.1% Length 427  
 best local similarity 100.0% Prod. No. 6,60043  
 Mismatch 1% Consensus 0% Mismatches 0% Indels 0% Gaps 0%

100.0% Score 12.0; 108.1% Length 427  
 best local similarity 100.0% Prod. No. 6,60043  
 Mismatch 1% Consensus 0% Mismatches 0% Indels 0% Gaps 0%

100.0% Score 12.0; 108.1% Length 427  
 best local similarity 100.0% Prod. No. 6,60043  
 Mismatch 1% Consensus 0% Mismatches 0% Indels 0% Gaps 0%

100.0% Score 12.0; 108.1% Length 427  
 best local similarity 100.0% Prod. No. 6,60043  
 Mismatch 1% Consensus 0% Mismatches 0% Indels 0% Gaps 0%

100.0% Score 12.0; 108.1% Length 427  
 best local similarity 100.0% Prod. No. 6,60043  
 Mismatch 1% Consensus 0% Mismatches 0% Indels 0% Gaps 0%

100.0% Score 12.0; 108.1% Length 427  
 best local similarity 100.0% Prod. No. 6,60043  
 Mismatch 1% Consensus 0% Mismatches 0% Indels 0% Gaps 0%

100.0% Score 12.0; 108.1% Length 427  
 best local similarity 100.0% Prod. No. 6,60043  
 Mismatch 1% Consensus 0% Mismatches 0% Indels 0% Gaps 0%

100.0% Score 12.0; 108.1% Length 427  
 best local similarity 100.0% Prod. No. 6,60043  
 Mismatch 1% Consensus 0% Mismatches 0% Indels 0% Gaps 0%

Ed. Bruce M. Johnson, of the University of North Carolina at Charlotte, and William E. Miller, of the University of Illinois at Chicago, with Edward F. Fennell, University of Illinois at Chicago, as authors.

[illegible][illegible][illegible]

Received 11 July 1994; accepted 12 October 1994

1. *Chlorophyll a* (Chl *a*)  
 2. *Chlorophyll b* (Chl *b*)  
 3. *Chlorophyll c* (Chl *c*)  
 4. *Chlorophyll d* (Chl *d*)  
 5. *Chlorophyll e* (Chl *e*)  
 6. *Chlorophyll f* (Chl *f*)  
 7. *Chlorophyll g* (Chl *g*)  
 8. *Chlorophyll h* (Chl *h*)  
 9. *Chlorophyll i* (Chl *i*)  
 10. *Chlorophyll j* (Chl *j*)  
 11. *Chlorophyll k* (Chl *k*)  
 12. *Chlorophyll l* (Chl *l*)  
 13. *Chlorophyll m* (Chl *m*)  
 14. *Chlorophyll n* (Chl *n*)  
 15. *Chlorophyll o* (Chl *o*)  
 16. *Chlorophyll p* (Chl *p*)  
 17. *Chlorophyll q* (Chl *q*)  
 18. *Chlorophyll r* (Chl *r*)  
 19. *Chlorophyll s* (Chl *s*)  
 20. *Chlorophyll t* (Chl *t*)  
 21. *Chlorophyll u* (Chl *u*)  
 22. *Chlorophyll v* (Chl *v*)  
 23. *Chlorophyll w* (Chl *w*)  
 24. *Chlorophyll x* (Chl *x*)  
 25. *Chlorophyll y* (Chl *y*)  
 26. *Chlorophyll z* (Chl *z*)  
 27. *Chlorophyll aa* (Chl *aa*)  
 28. *Chlorophyll ab* (Chl *ab*)  
 29. *Chlorophyll ac* (Chl *ac*)  
 30. *Chlorophyll ad* (Chl *ad*)  
 31. *Chlorophyll ae* (Chl *ae*)  
 32. *Chlorophyll af* (Chl *af*)  
 33. *Chlorophyll ag* (Chl *ag*)  
 34. *Chlorophyll ah* (Chl *ah*)  
 35. *Chlorophyll ai* (Chl *ai*)  
 36. *Chlorophyll aj* (Chl *aj*)  
 37. *Chlorophyll ak* (Chl *ak*)  
 38. *Chlorophyll al* (Chl *al*)  
 39. *Chlorophyll am* (Chl *am*)  
 40. *Chlorophyll an* (Chl *an*)  
 41. *Chlorophyll ao* (Chl *ao*)  
 42. *Chlorophyll ap* (Chl *ap*)  
 43. *Chlorophyll aq* (Chl *aq*)  
 44. *Chlorophyll ar* (Chl *ar*)  
 45. *Chlorophyll as* (Chl *as*)  
 46. *Chlorophyll at* (Chl *at*)  
 47. *Chlorophyll au* (Chl *au*)  
 48. *Chlorophyll av* (Chl *av*)  
 49. *Chlorophyll aw* (Chl *aw*)  
 50. *Chlorophyll ax* (Chl *ax*)  
 51. *Chlorophyll ay* (Chl *ay*)  
 52. *Chlorophyll az* (Chl *az*)  
 53. *Chlorophyll aza* (Chl *aza*)  
 54. *Chlorophyll abz* (Chl *abz*)  
 55. *Chlorophyll aca* (Chl *aca*)  
 56. *Chlorophyll acb* (Chl *acb*)  
 57. *Chlorophyll acc* (Chl *acc*)  
 58. *Chlorophyll acd* (Chl *acd*)  
 59. *Chlorophyll ace* (Chl *ace*)  
 60. *Chlorophyll acf* (Chl *acf*)  
 61. *Chlorophyll acg* (Chl *acg*)  
 62. *Chlorophyll ach* (Chl *ach*)  
 63. *Chlorophyll aci* (Chl *aci*)  
 64. *Chlorophyll acj* (Chl *acj*)  
 65. *Chlorophyll ack* (Chl *ack*)  
 66. *Chlorophyll acl* (Chl *acl*)  
 67. *Chlorophyll acm* (Chl *acm*)  
 68. *Chlorophyll acn* (Chl *acn*)  
 69. *Chlorophyll aco* (Chl *aco*)  
 70. *Chlorophyll acp* (Chl *acp*)  
 71. *Chlorophyll acq* (Chl *acq*)  
 72. *Chlorophyll acr* (Chl *acr*)  
 73. *Chlorophyll acs* (Chl *acs*)  
 74. *Chlorophyll act* (Chl *act*)  
 75. *Chlorophyll acu* (Chl *acu*)  
 76. *Chlorophyll acv* (Chl *acv*)  
 77. *Chlorophyll acw* (Chl *acw*)  
 78. *Chlorophyll acx* (Chl *acx*)  
 79. *Chlorophyll acy* (Chl *acy*)  
 80. *Chlorophyll acz* (Chl *acz*)  
 81. *Chlorophyll azaa* (Chl *aza*)  
 82. *Chlorophyll abz* (Chl *abz*)  
 83. *Chlorophyll aca* (Chl *aca*)  
 84. *Chlorophyll acb* (Chl *acb*)  
 85. *Chlorophyll acc* (Chl *acc*)  
 86. *Chlorophyll acd* (Chl *acd*)  
 87. *Chlorophyll ace* (Chl *ace*)  
 88. *Chlorophyll acf* (Chl *acf*)  
 89. *Chlorophyll acg* (Chl *acg*)  
 90. *Chlorophyll ach* (Chl *ach*)  
 91. *Chlorophyll aci* (Chl *aci*)  
 92. *Chlorophyll acj* (Chl *acj*)  
 93. *Chlorophyll ack* (Chl *ack*)  
 94. *Chlorophyll acl* (Chl *acl*)  
 95. *Chlorophyll acm* (Chl *acm*)  
 96. *Chlorophyll acn* (Chl *acn*)  
 97. *Chlorophyll aco* (Chl *aco*)  
 98. *Chlorophyll acp* (Chl *acp*)  
 99. *Chlorophyll acq* (Chl *acq*)  
 100. *Chlorophyll acr* (Chl *acr*)  
 101. *Chlorophyll acs* (Chl *acs*)  
 102. *Chlorophyll act* (Chl *act*)  
 103. *Chlorophyll acu* (Chl *acu*)  
 104. *Chlorophyll acv* (Chl *acv*)  
 105. *Chlorophyll acw* (Chl *acw*)  
 106. *Chlorophyll acx* (Chl *acx*)  
 107. *Chlorophyll acy* (Chl *acy*)  
 108. *Chlorophyll acz* (Chl *acz*)  
 109. *Chlorophyll azaa* (Chl *aza*)  
 110. *Chlorophyll abz* (Chl *abz*)  
 111. *Chlorophyll aca* (Chl *aca*)  
 112. *Chlorophyll acb* (Chl *acb*)  
 113. *Chlorophyll acc* (Chl *acc*)  
 114. *Chlorophyll acd* (Chl *acd*)  
 115. *Chlorophyll ace* (Chl *ace*)  
 116. *Chlorophyll acf* (Chl *acf*)  
 117. *Chlorophyll acg* (Chl *acg*)  
 118. *Chlorophyll ach* (Chl *ach*)  
 119. *Chlorophyll aci* (Chl *aci*)  
 120. *Chlorophyll acj* (Chl *acj*)  
 121. *Chlorophyll ack* (Chl *ack*)  
 122. *Chlorophyll acl* (Chl *acl*)  
 123. *Chlorophyll acm* (Chl *acm*)  
 124. *Chlorophyll acn* (Chl *acn*)  
 125. *Chlorophyll aco* (Chl *aco*)  
 126. *Chlorophyll acp* (Chl *acp*)  
 127. *Chlorophyll acq* (Chl *acq*)  
 128. *Chlorophyll acr* (Chl *acr*)  
 129. *Chlorophyll acs* (Chl *acs*)  
 130. *Chlorophyll act* (Chl *act*)  
 131. *Chlorophyll acu* (Chl *acu*)  
 132. *Chlorophyll acv* (Chl *acv*)  
 133. *Chlorophyll acw* (Chl *acw*)  
 134. *Chlor*

[illegible][illegible]

Math. Biosci. 111:111-126, 1993. © 1993 Kluwer Academic Publishers. Printed in the Netherlands.

[illegible][illegible][illegible]

STUDIES IN THE HISTORY OF THE LITERATURE OF THE UNITED STATES  
 EDITED BY  
 J. G. P. BAKER  
 VOLUME 1  
 THE LITERATURE OF THE UNITED STATES  
 BY  
 J. G. P. BAKER  
 NEW YORK  
 THE UNIVERSITY OF CHICAGO PRESS  
 1962

Edward Lewis, M.D., Ph.D.,  
 DNA Laboratory, Howard Hughes  
 Medical Institute, University of  
 Washington, Seattle, Washington

to deal with the  $\mathcal{M}_A$  and  $\mathcal{M}_B$  sectors, and the  $\mathcal{M}_A$  and  $\mathcal{M}_B$  sectors are separated by the action of  $\mathcal{G}H/\mathcal{G}$  (see eq. (3.1)).

[illegible][illegible]

to achieve the desired effect of "and was not known to be a (d) pattern" results in a "not known to be a (d) pattern" result. The National and Local Planning

FASTA format. Library is normalised. Library was constructed by Intron, Sequences and BLAST time limitation.

FASTA format. Library is normalised. Library was constructed by Intron, Sequences and BLAST time limitation.

FASTA format. Library is normalised. Library was constructed by Intron, Sequences and BLAST time limitation.

FASTA format. Library is normalised. Library was constructed by Intron, Sequences and BLAST time limitation.

FASTA format. Library is normalised. Library was constructed by Intron, Sequences and BLAST time limitation.

FASTA format. Library is normalised. Library was constructed by Intron, Sequences and BLAST time limitation.

FASTA format. Library is normalised. Library was constructed by Intron, Sequences and BLAST time limitation.

FASTA format. Library is normalised. Library was constructed by Intron, Sequences and BLAST time limitation.

FASTA format. Library is normalised. Library was constructed by Intron, Sequences and BLAST time limitation.

FASTA format. Library is normalised. Library was constructed by Intron, Sequences and BLAST time limitation.

FASTA format. Library is normalised. Library was constructed by Intron, Sequences and BLAST time limitation.

FASTA format. Library is normalised. Library was constructed by Intron, Sequences and BLAST time limitation.

FASTA format. Library is normalised. Library was constructed by Intron, Sequences and BLAST time limitation.

FASTA format. Library is normalised. Library was constructed by Intron, Sequences and BLAST time limitation.

FASTA format. Library is normalised. Library was constructed by Intron, Sequences and BLAST time limitation.

FASTA format. Library is normalised. Library was constructed by Intron, Sequences and BLAST time limitation.

FASTA format. Library is normalised. Library was constructed by Intron, Sequences and BLAST time limitation.

Mon Feb 11 09:19:55 2002

us-10-006-430-68.szlm60.rst

Page 8

Copyright (c) 1994-2000 Compucon Ltd.

of the source, using the method

February 9, 2002, 11:44:07, Source Time: 2519.49 seconds

(without adjustments)

10.962 Million cell updates/sec

10.962 Million cell updates/sec

10.962 Million cell updates/sec

10.962 Million cell updates/sec

10.962 Million cell updates/sec

10.962 Million cell updates/sec

10.962 Million cell updates/sec

10.962 Million cell updates/sec

10.962 Million cell updates/sec

10.962 Million cell updates/sec

10.962 Million cell updates/sec

10.962 Million cell updates/sec

10.962 Million cell updates/sec

10.962 Million cell updates/sec

10.962 Million cell updates/sec

10.962 Million cell updates/sec

10.962 Million cell updates/sec

10.962 Million cell updates/sec

10.962 Million cell updates/sec

10.962 Million cell updates/sec

10.962 Million cell updates/sec

10.962 Million cell updates/sec

10.962 Million cell updates/sec

10.962 Million cell updates/sec

10.962 Million cell updates/sec

10.962 Million cell updates/sec

10.962 Million cell updates/sec

10.962 Million cell updates/sec

10.962 Million cell updates/sec

10.962 Million cell updates/sec

10.962 Million cell updates/sec

10.962 Million cell updates/sec

10.962 Million cell updates/sec

10.962 Million cell updates/sec

10.962 Million cell updates/sec

10.962 Million cell updates/sec

10.962 Million cell updates/sec

Result No. Source Match Length dB

1 13.2 66.0 49 6

2 13.2 66.0 49 6

3 13.2 66.0 49 6

4 13.2 66.0 49 6

5 13.2 66.0 49 6

6 13.2 66.0 49 6

7 13.2 66.0 49 6

8 13.2 66.0 49 6

9 13.2 66.0 49 6

10 13.2 66.0 49 6

11 13.2 66.0 49 6

12 13.2 66.0 49 6

13 13.2 66.0 49 6

14 13.2 66.0 49 6

15 13.2 66.0 49 6

16 13.2 66.0 49 6

17 13.2 66.0 49 6

18 13.2 66.0 49 6

19 13.2 66.0 49 6

20 13.2 66.0 49 6

21 13.2 66.0 49 6

22 13.2 66.0 49 6

23 13.2 66.0 49 6

24 13.2 66.0 49 6

25 13.2 66.0 49 6

26 13.2 66.0 49 6

27 13.2 66.0 49 6

28 13.2 66.0 49 6

29 13.2 66.0 49 6

30 13.2 66.0 49 6

31 13.2 66.0 49 6

32 13.2 66.0 49 6

33 13.2 66.0 49 6

34 13.2 66.0 49 6

35 13.2 66.0 49 6

36 13.2 66.0 49 6

37 13.2 66.0 49 6

38 13.2 66.0 49 6

39 13.2 66.0 49 6

40 13.2 66.0 49 6

41 13.2 66.0 49 6

Result No. Source Match Length dB

1 13.2 66.0 49 6

2 13.2 66.0 49 6

3 13.2 66.0 49 6

4 13.2 66.0 49 6

5 13.2 66.0 49 6

6 13.2 66.0 49 6

7 13.2 66.0 49 6

8 13.2 66.0 49 6

9 13.2 66.0 49 6

10 13.2 66.0 49 6

11 13.2 66.0 49 6

12 13.2 66.0 49 6

13 13.2 66.0 49 6

14 13.2 66.0 49 6

15 13.2 66.0 49 6

16 13.2 66.0 49 6

17 13.2 66.0 49 6

18 13.2 66.0 49 6

19 13.2 66.0 49 6

20 13.2 66.0 49 6

21 13.2 66.0 49 6

22 13.2 66.0 49 6

23 13.2 66.0 49 6

24 13.2 66.0 49 6

25 13.2 66.0 49 6

26 13.2 66.0 49 6

27 13.2 66.0 49 6

28 13.2 66.0 49 6

29 13.2 66.0 49 6

30 13.2 66.0 49 6

31 13.2 66.0 49 6

32 13.2 66.0 49 6

33 13.2 66.0 49 6

34 13.2 66.0 49 6

35 13.2 66.0 49 6

36 13.2 66.0 49 6

37 13.2 66.0 49 6

38 13.2 66.0 49 6

39 13.2 66.0 49 6

40 13.2 66.0 49 6

41 13.2 66.0 49 6

~~SECRET~~

SECRET  
 1. The following information was obtained from a review of the files of the Central Intelligence Agency, Department of Defense, and the Department of State, and is being furnished to you for your information.

2. The following information was obtained from a review of the files of the Central Intelligence Agency, Department of Defense, and the Department of State, and is being furnished to you for your information.

3. The following information was obtained from a review of the files of the Central Intelligence Agency, Department of Defense, and the Department of State, and is being furnished to you for your information.

4. The following information was obtained from a review of the files of the Central Intelligence Agency, Department of Defense, and the Department of State, and is being furnished to you for your information.

5. The following information was obtained from a review of the files of the Central Intelligence Agency, Department of Defense, and the Department of State, and is being furnished to you for your information.

6. The following information was obtained from a review of the files of the Central Intelligence Agency, Department of Defense, and the Department of State, and is being furnished to you for your information.

7. The following information was obtained from a review of the files of the Central Intelligence Agency, Department of Defense, and the Department of State, and is being furnished to you for your information.

















[illegible]
$$u_{\alpha} = \frac{1}{N_{\alpha}} \sum_{i=1}^{N_{\alpha}} u_{\alpha i} \quad \text{and} \quad \sigma_{\alpha}^2 = \frac{1}{N_{\alpha}} \sum_{i=1}^{N_{\alpha}} u_{\alpha i}^2 - u_{\alpha}^2$$
[illegible]

1997. *Mathematical models of the spread of infectious diseases*. Cambridge University Press, Cambridge.

2000. *Mathematical epidemiology*. John Wiley & Sons, New York.

2002. *Mathematical models of infectious diseases*. Cambridge University Press, Cambridge.

2003. *Mathematical epidemiology and statistics*. Cambridge University Press, Cambridge.

2004. *Mathematical models of infectious diseases*. Cambridge University Press, Cambridge.

2005. *Mathematical models of infectious diseases*. Cambridge University Press, Cambridge.

2006. *Mathematical models of infectious diseases*. Cambridge University Press, Cambridge.

2007. *Mathematical models of infectious diseases*. Cambridge University Press, Cambridge.

2008. *Mathematical models of infectious diseases*. Cambridge University Press, Cambridge.

2009. *Mathematical models of infectious diseases*. Cambridge University Press, Cambridge.

2010. *Mathematical models of infectious diseases*. Cambridge University Press, Cambridge.

2011. *Mathematical models of infectious diseases*. Cambridge University Press, Cambridge.

2012. *Mathematical models of infectious diseases*. Cambridge University Press, Cambridge.

2013. *Mathematical models of infectious diseases*. Cambridge University Press, Cambridge.

2014. *Mathematical models of infectious diseases*. Cambridge University Press, Cambridge.

2015. *Mathematical models of infectious diseases*. Cambridge University Press, Cambridge.

2016. *Mathematical models of infectious diseases*. Cambridge University Press, Cambridge.

2017. *Mathematical models of infectious diseases*. Cambridge University Press, Cambridge.

2018. *Mathematical models of infectious diseases*. Cambridge University Press, Cambridge.

2019. *Mathematical models of infectious diseases*. Cambridge University Press, Cambridge.

2020. *Mathematical models of infectious diseases*. Cambridge University Press, Cambridge.

2021. *Mathematical models of infectious diseases*. Cambridge University Press, Cambridge.

2022. *Mathematical models of infectious diseases*. Cambridge University Press, Cambridge.

2023. *Mathematical models of infectious diseases*. Cambridge University Press, Cambridge.

2024. *Mathematical models of infectious diseases*. Cambridge University Press, Cambridge.

2025. *Mathematical models of infectious diseases*. Cambridge University Press, Cambridge.

[illegible][illegible][illegible]

1. The first part of the paper is devoted to the study of the asymptotic behavior of the solutions of the system of equations (1) as  $\epsilon \rightarrow 0$ . It is shown that the solutions of the system (1) converge to the solutions of the system of equations (2) as  $\epsilon \rightarrow 0$ .

[illegible]

the  $3'$  ends of the transcripts. The  $5'$  ends of the transcripts were labeled with  $^{32}\text{P}$ -labeled ATP. The RNA was hydrolyzed and analyzed by electrophoresis on 10% polyacrylamide gels. The RNA was transferred to a Gene-Screen Plus membrane and probed with a  $^{32}\text{P}$ -labeled cDNA probe. The probe was prepared by PCR amplification of the cDNA template. The PCR products were purified by gel extraction and labeled with  $^{32}\text{P}$ -labeled dNTPs. The labeled cDNA probe was hybridized to the RNA on the membrane. The hybrid was washed and detected by autoradiography.

Author	Year	Country	Sample Size	Study Design	Findings
Smith et al.	2015	USA	1,200	Longitudinal	Increased risk of depression in children of parents with mental illness.
Johnson et al.	2016	UK	800	Cross-sectional	Higher levels of anxiety in children of parents with anxiety disorders.
Williams et al.	2017	Canada	1,500	Family Study	Genetic factors play a significant role in the transmission of mental illness.
Chen et al.	2018	China	2,000	Case-control	Environmental factors contribute to the development of mental illness in children.
Miller et al.	2019	Australia	900	Longitudinal	Early intervention can significantly reduce the risk of mental illness in children.
Lee et al.	2020	South Korea	1,100	Cohort Study	Parental mental health status is a strong predictor of child mental health outcomes.
Wong et al.	2021	India	1,300	Family Study	Cultural factors influence the expression and management of mental illness.
Nguyen et al.	2022	Vietnam	1,400	Longitudinal	Stressful life events increase the risk of mental illness in children.
Patel et al.	2023	South Africa	1,600	Cross-sectional	Socioeconomic factors are closely linked to the prevalence of mental illness.
Kim et al.	2024	Japan	1,700	Family Study	Genetic and environmental factors interact to influence mental health.
Alvarez et al.	2025	Spain	1,800	Longitudinal	Parental mental health interventions can improve child mental health.

Variable	Unit	Mean	SD	NA
Age (years)	years	65.4	10.1	1
Gender	Male/Female	50/50		
Education (years)	years	12.5	2.1	1
Marital status	Married/Single/Divorced/Widowed	45/15/10/10		
Income (€)	€	1500	500	1
Health status	Good/Fair/Poor	30/40/30		
Medication	Yes/No	20/30		
Smoking status	Smoker/Non-smoker	10/40		
Alcohol consumption	Yes/No	15/15		
Comorbidities	Hypertension/Diabetes/Cholesterol	20/10/10		
Family history	Yes/No	10/10		
Psychological factors	Anxiety/Depression	10/10		
Social support	High/Low	20/10		
Healthcare utilization	Regular/Infrequent	15/15		
Health insurance	Public/Private	30/10		
Healthcare costs	€	500	200	1
Healthcare satisfaction	High/Low	20/10		
Healthcare accessibility	High/Low	20/10		
Healthcare quality	High/Low	20/10		
Healthcare safety	High/Low	20/10		
Healthcare effectiveness	High/Low	20/10		
Healthcare equity	High/Low	20/10		
Healthcare sustainability	High/Low	20/10		
Healthcare transparency	High/Low	20/10		
Healthcare accountability	High/Low	20/10		
Healthcare responsiveness	High/Low	20/10		
Healthcare patient-centeredness	High/Low	20/10		
Healthcare cultural competence	High/Low	20/10		
Healthcare communication	High/Low	20/10		
Healthcare collaboration	High/Low	20/10		
Healthcare leadership	High/Low	20/10		
Healthcare governance	High/Low	20/10		
Healthcare innovation	High/Low	20/10		
Healthcare research	High/Low	20/10		
Healthcare education	High/Low	20/10		
Healthcare workforce	High/Low	20/10		
Healthcare infrastructure	High/Low	20/10		
Healthcare information technology	High/Low	20/10		
Healthcare data management	High/Low	20/10		
Healthcare quality improvement	High/Low	20/10		
Healthcare patient engagement	High/Low	20/10		
Healthcare patient empowerment	High/Low	20/10		
Healthcare patient education	High/Low	20/10		
Healthcare patient participation	High/Low	20/10		
Healthcare patient advocacy	High/Low	20/10		
Healthcare patient feedback	High/Low	20/10		
Healthcare patient satisfaction	High/Low	20/10		
Healthcare patient loyalty	High/Low	20/10		
Healthcare patient retention	High/Low	20/10		
Healthcare patient referral	High/Low	20/10		
Healthcare patient recommendation	High/Low	20/10		
Healthcare patient endorsement	High/Low	20/10		
Healthcare patient testimonial	High/Low	20/10		
Healthcare patient review	High/Low	20/10		
Healthcare patient rating	High/Low	20/10		
Healthcare patient score	High/Low	20/10		
Healthcare patient grade	High/Low	20/10		
Healthcare patient mark	High/Low	20/10		
Healthcare patient result	High/Low	20/10		
Healthcare patient outcome	High/Low	20/10		
Healthcare patient impact	High/Low	20/10		
Healthcare patient effect	High/Low	20/10		
Healthcare patient influence	High/Low	20/10		
Healthcare patient power	High/Low	20/10		
Healthcare patient authority	High/Low	20/10		
Healthcare patient prestige	High/Low	20/10		
Healthcare patient reputation	High/Low	20/10		
Healthcare patient status	High/Low	20/10		
Healthcare patient position	High/Low	20/10		
Healthcare patient role	High/Low	20/10		
Healthcare patient function	High/Low	20/10		
Healthcare patient duty	High/Low	20/10		
Healthcare patient obligation	High/Low	20/10		
Healthcare patient responsibility	High/Low	20/10		
Healthcare patient accountability	High/Low	20/10		
Healthcare patient answerability	High/Low	20/10		
Healthcare patient liability	High/Low	20/10		
Healthcare patient responsibility	High/Low	20/10		
Healthcare patient obligation	High/Low	20/10		
Healthcare patient duty	High/Low	20/10		
Healthcare patient function	High/Low	20/10		
Healthcare patient role	High/Low	20/10		
Healthcare patient position	High/Low	20/10		
Healthcare patient status	High/Low	20/10		
Healthcare patient position	High/Low	20/10		
Healthcare patient role	High/Low	20/10		

REPRINTED  
AUTHOR'S  
TITLE  
JOURNAL  
VOLUME  
NUMBER  
DATE

Finally, we also evaluated the effect of the addition of a small amount of  $\text{H}_2$  ( $\text{H}_2/\text{CO} = 0.05$ ) to the syngas. It was found that the addition of  $\text{H}_2$  to the syngas improved the selectivity of the reaction of  $\text{CO}$  to  $\text{CH}_3\text{OH}$  and  $\text{CH}_3\text{OCH}_3$  and reduced the selectivity of the reaction of  $\text{CO}$  to  $\text{CH}_3\text{CHO}$  and  $\text{CH}_3\text{COCH}_3$ . The selectivity of the reaction of  $\text{CO}$  to  $\text{CH}_3\text{OH}$  and  $\text{CH}_3\text{OCH}_3$  was improved by 10% and 15%, respectively, and the selectivity of the reaction of  $\text{CO}$  to  $\text{CH}_3\text{CHO}$  and  $\text{CH}_3\text{COCH}_3$  was reduced by 5% and 10%, respectively.

[illegible]

Mathewson, J. and S. J. Liebowitz (1990) "Business Cycles and the Role of the Firm," *Journal of Economic Surveys* 4, 1-26.

[illegible][illegible]









Mon Feb 11 09:19:57 2002

us-10-006-430-75.szlm60.rst

Page 9





[illegible]

100

[illegible]

LEUNG, T. C., M. T. CHAN, S. C. CHAN, and J. C. WONG. 1992. The effects of water quality on the reproductive performance of the Chinese mud carp (*Varicorhinus sinensis*) in a polluted river. *Environmental Pollution* 74:1-11.

[illegible][illegible][illegible]

THE UNIVERSITY OF CHICAGO  
 5408 S. UNIVERSITY AVE.  
 CHICAGO, ILL. 60637  
 U.S.A.  
 TEL: 773/936-5000  
 FAX: 773/936-5000  
 E-MAIL: JOURNAL@CHICAGO.EDU  
 WWW: WWW.CHICAGO.EDU

1. Atrial fibrillation (AF) is a common cardiac arrhythmia characterized by irregular and rapid heartbeats. It is often associated with underlying structural heart disease, such as coronary artery disease, hypertension, and heart failure. AF can lead to stroke, heart failure, and other complications if not properly managed.

2. The management of AF typically involves a combination of lifestyle modifications, medications, and procedures. Lifestyle changes, such as maintaining a healthy weight, exercising regularly, and avoiding alcohol and tobacco, can help reduce the risk of AF. Medications, including beta-blockers, calcium channel blockers, and antiarrhythmics, are used to control the heart rate and rhythm. Procedures, such as catheter ablation and surgical ablation, are used to eliminate the areas of the heart that trigger AF.

3. In addition to medical management, patients with AF should also be aware of potential complications and when to seek medical attention. Symptoms of AF, such as palpitations, dizziness, and shortness of breath, should be reported to a healthcare provider. Patients should also be aware of the risk of stroke and the importance of taking blood thinners as prescribed.

4. Overall, the management of AF requires a multidisciplinary approach involving a cardiologist, a primary care physician, and a patient. Regular follow-up and communication are essential for successful outcomes.

**TABLE III**  
Composition of the Polymers

Sample	Monomer	Co-monomer	Initiator
1	Styrene	None	None
2	Styrene	None	None
3	Styrene	None	None
4	Styrene	None	None
5	Styrene	None	None
6	Styrene	None	None
7	Styrene	None	None
8	Styrene	None	None
9	Styrene	None	None
10	Styrene	None	None
11	Styrene	None	None
12	Styrene	None	None
13	Styrene	None	None
14	Styrene	None	None
15	Styrene	None	None
16	Styrene	None	None
17	Styrene	None	None
18	Styrene	None	None
19	Styrene	None	None
20	Styrene	None	None
21	Styrene	None	None
22	Styrene	None	None
23	Styrene	None	None
24	Styrene	None	None
25	Styrene	None	None
26	Styrene	None	None
27	Styrene	None	None
28	Styrene	None	None
29	Styrene	None	None
30	Styrene	None	None
31	Styrene	None	None
32	Styrene	None	None
33	Styrene	None	None
34	Styrene	None	None
35	Styrene	None	None
36	Styrene	None	None
37	Styrene	None	None
38	Styrene	None	None
39	Styrene	None	None
40	Styrene	None	None
41	Styrene	None	None
42	Styrene	None	None
43	Styrene	None	None
44	Styrene	None	None
45	Styrene	None	None
46	Styrene	None	None
47	Styrene	None	None
48	Styrene	None	None
49	Styrene	None	None
50	Styrene	None	None
51	Styrene	None	None
52	Styrene	None	None
53	Styrene	None	None
54	Styrene	None	None
55	Styrene	None	None
56	Styrene	None	None
57	Styrene	None	None
58	Styrene	None	None
59	Styrene	None	None
60	Styrene	None	None
61	Styrene	None	None
62	Styrene	None	None
63	Styrene	None	None
64	Styrene	None	None
65	Styrene	None	None
66	Styrene	None	None
67	Styrene	None	None
68	Styrene	None	None
69	Styrene	None	None
70	Styrene	None	None
71	Styrene	None	None
72	Styrene	None	None
73	Styrene	None	None
74	Styrene	None	None
75	Styrene	None	None
76	Styrene	None	None
77	Styrene	None	None
78	Styrene	None	None
79	Styrene	None	None
80	Styrene	None	None
81	Styrene	None	None
82	Styrene	None	None
83	Styrene	None	None
84	Styrene	None	None
85	Styrene	None	None
86	Styrene	None	None
87	Styrene	None	None
88	Styrene	None	None
89	Styrene	None	None
90	Styrene	None	None
91	Styrene	None	None
92	Styrene	None	None
93	Styrene	None	None
94	Styrene	None	None
95	Styrene	None	None
96	Styrene	None	None
97	Styrene	None	None
98	Styrene	None	None
99	Styrene	None	None
100	Styrene	None	None

[illegible][illegible]

Author	Year	Country	Sample Size	Study Design	Outcome
Allen et al.	1998	USA	1,000	Case-control	Increased risk of SIDS
Anderson et al.	1999	USA	1,000	Case-control	Increased risk of SIDS
Baron et al.	1999	USA	1,000	Case-control	Increased risk of SIDS
Baron et al.	2000	USA	1,000	Case-control	Increased risk of SIDS
Baron et al.	2001	USA	1,000	Case-control	Increased risk of SIDS
Baron et al.	2002	USA	1,000	Case-control	Increased risk of SIDS
Baron et al.	2003	USA	1,000	Case-control	Increased risk of SIDS
Baron et al.	2004	USA	1,000	Case-control	Increased risk of SIDS
Baron et al.	2005	USA	1,000	Case-control	Increased risk of SIDS
Baron et al.	2006	USA	1,000	Case-control	Increased risk of SIDS
Baron et al.	2007	USA	1,000	Case-control	Increased risk of SIDS
Baron et al.	2008	USA	1,000	Case-control	Increased risk of SIDS
Baron et al.	2009	USA	1,000	Case-control	Increased risk of SIDS
Baron et al.	2010	USA	1,000	Case-control	Increased risk of SIDS
Baron et al.	2011	USA	1,000	Case-control	Increased risk of SIDS
Baron et al.	2012	USA	1,000	Case-control	Increased risk of SIDS
Baron et al.	2013	USA	1,000	Case-control	Increased risk of SIDS
Baron et al.	2014	USA	1,000	Case-control	Increased risk of SIDS
Baron et al.	2015	USA	1,000	Case-control	Increased risk of SIDS
Baron et al.	2016	USA	1,000	Case-control	Increased risk of SIDS
Baron et al.	2017	USA	1,000	Case-control	Increased risk of SIDS
Baron et al.	2018	USA	1,000	Case-control	Increased risk of SIDS
Baron et al.	2019	USA	1,000	Case-control	Increased risk of SIDS
Baron et al.	2020	USA	1,000	Case-control	Increased risk of SIDS
Baron et al.	2021	USA	1,000	Case-control	Increased risk of SIDS
Baron et al.	2022	USA	1,000	Case-control	Increased risk of SIDS
Baron et al.	2023	USA	1,000	Case-control	Increased risk of SIDS
Baron et al.	2024	USA	1,000	Case-control	Increased risk of SIDS
Baron et al.	2025	USA	1,000	Case-control	Increased risk of SIDS

[illegible]

*Z. für Naturforschung*, 1968, 23a, 70-71.  
Zusammenfassung: Die Polymerisation von Acrylnitril im flüssigen Stickstoff.

[illegible]

STUDY	STUDY TYPE	STUDY YEAR	STUDY LOCATION	STUDY PERIOD	STUDY DESIGN	STUDY POPULATION	STUDY SAMPLE SIZE	STUDY RESULTS	STUDY CONCLUSIONS
1	Case-control	1998-2000	USA	1998-2000	Case-control	1000 cases, 1000 controls	1000	OR = 1.5, 95% CI = 1.2-1.8	Increased risk of lung cancer with smoking
2	Cohort	1995-2005	UK	1995-2005	Cohort	5000 participants	5000	HR = 1.2, 95% CI = 1.1-1.3	Increased risk of heart disease with smoking
3	Case-control	2001-2003	Canada	2001-2003	Case-control	200 cases, 200 controls	200	OR = 1.8, 95% CI = 1.5-2.1	Increased risk of breast cancer with smoking
4	Cohort	2000-2008	USA	2000-2008	Cohort	1000 participants	1000	HR = 1.1, 95% CI = 1.0-1.2	Increased risk of lung cancer with smoking
5	Case-control	1999-2001	UK	1999-2001	Case-control	150 cases, 150 controls	150	OR = 1.6, 95% CI = 1.3-1.9	Increased risk of prostate cancer with smoking
6	Cohort	2002-2006	USA	2002-2006	Cohort	2000 participants	2000	HR = 1.3, 95% CI = 1.2-1.4	Increased risk of heart disease with smoking
7	Case-control	2003-2005	Canada	2003-2005	Case-control	300 cases, 300 controls	300	OR = 1.7, 95% CI = 1.4-2.0	Increased risk of lung cancer with smoking
8	Cohort	2004-2007	UK	2004-2007	Cohort	1500 participants	1500	HR = 1.2, 95% CI = 1.1-1.3	Increased risk of heart disease with smoking
9	Case-control	2005-2007	USA	2005-2007	Case-control	400 cases, 400 controls	400	OR = 1.9, 95% CI = 1.6-2.2	Increased risk of breast cancer with smoking
10	Cohort	2006-2009	Canada	2006-2009	Cohort	2500 participants	2500	HR = 1.1, 95% CI = 1.0-1.2	Increased risk of lung cancer with smoking

STRUCTURE	FUNCTION
CELLULOSE	Structural support
CHLOROPHYLL	Photosynthesis
ACID-BASE	Regulation of pH
GLUCOSE	Energy source









Mon Feb 11 09:19:58 2002

us-10-006-430-76.szlm60.rge

Page 6



RE: "HUMAN RIGHTS"

TO: "HUMAN RIGHTS" (10-006-430-88)

FROM: "HUMAN RIGHTS" (10-006-430-88)

RE: "HUMAN RIGHTS" (10-006-430-88)

TO: "HUMAN RIGHTS" (10-006-430-88)

FROM: "HUMAN RIGHTS" (10-006-430-88)

RE: "HUMAN RIGHTS" (10-006-430-88)

TO: "HUMAN RIGHTS" (10-006-430-88)

FROM: "HUMAN RIGHTS" (10-006-430-88)

RE: "HUMAN RIGHTS" (10-006-430-88)

TO: "HUMAN RIGHTS" (10-006-430-88)

FROM: "HUMAN RIGHTS" (10-006-430-88)

RE: "HUMAN RIGHTS" (10-006-430-88)

TO: "HUMAN RIGHTS" (10-006-430-88)

FROM: "HUMAN RIGHTS" (10-006-430-88)

RE: "HUMAN RIGHTS" (10-006-430-88)

TO: "HUMAN RIGHTS" (10-006-430-88)

FROM: "HUMAN RIGHTS" (10-006-430-88)

RE: "HUMAN RIGHTS" (10-006-430-88)

TO: "HUMAN RIGHTS" (10-006-430-88)

FROM: "HUMAN RIGHTS" (10-006-430-88)

RE: "HUMAN RIGHTS" (10-006-430-88)

TO: "HUMAN RIGHTS" (10-006-430-88)

FROM: "HUMAN RIGHTS" (10-006-430-88)

RE: "HUMAN RIGHTS" (10-006-430-88)

TO: "HUMAN RIGHTS" (10-006-430-88)

FROM: "HUMAN RIGHTS" (10-006-430-88)

RE: "HUMAN RIGHTS" (10-006-430-88)

TO: "HUMAN RIGHTS" (10-006-430-88)

FROM: "HUMAN RIGHTS" (10-006-430-88)

RE: "HUMAN RIGHTS" (10-006-430-88)

TO: "HUMAN RIGHTS" (10-006-430-88)

FROM: "HUMAN RIGHTS" (10-006-430-88)

RE: "HUMAN RIGHTS" (10-006-430-88)

TO: "HUMAN RIGHTS" (10-006-430-88)

FROM: "HUMAN RIGHTS" (10-006-430-88)



Figure 1. The effect of the concentration of the monomer on the polymerization of MMA initiated by  $\text{Ti}(\text{O}i\text{Pr})_4$  in the presence of  $\text{Sn}(\text{O}i\text{Pr})_4$  at  $100^\circ\text{C}$  for 24 h. The concentration of  $\text{Sn}(\text{O}i\text{Pr})_4$  was 0.01 mol/L. The concentration of  $\text{Ti}(\text{O}i\text{Pr})_4$  was 0.01 mol/L. The concentration of MMA was 0.5 mol/L. The concentration of  $\text{Sn}(\text{O}i\text{Pr})_4$  was 0.01 mol/L. The concentration of  $\text{Ti}(\text{O}i\text{Pr})_4$  was 0.01 mol/L. The concentration of MMA was 0.5 mol/L.

Figure 1. The effect of the concentration of the *Agrobacterium* suspension on the transformation efficiency of *Agrobacterium* strains. The *Agrobacterium* strains were cultured in YEA medium for 24 h at 28 °C. The cell concentration of the strains was adjusted to 1.0 × 10<sup>8</sup> cells/ml. The cell suspension was then diluted with distilled water to obtain the concentrations of 1.0 × 10<sup>7</sup>, 1.0 × 10<sup>6</sup>, 1.0 × 10<sup>5</sup>, 1.0 × 10<sup>4</sup>, 1.0 × 10<sup>3</sup>, 1.0 × 10<sup>2</sup>, 1.0 × 10<sup>1</sup>, and 1.0 × 10<sup>0</sup> cells/ml. The cell suspension was then inoculated into the plant tissue. The transformation efficiency was determined by the number of transformants per 100 mg of plant tissue. The data were expressed as the mean ± SD of three independent experiments.

[illegible][illegible][illegible]

Country	Area	Population	Year
China	1,000,000	1,000,000	1990
India	1,000,000	1,000,000	1990
USA	1,000,000	1,000,000	1990
UK	1,000,000	1,000,000	1990
France	1,000,000	1,000,000	1990
Germany	1,000,000	1,000,000	1990
Italy	1,000,000	1,000,000	1990
Spain	1,000,000	1,000,000	1990
Japan	1,000,000	1,000,000	1990
South Korea	1,000,000	1,000,000	1990
Taiwan	1,000,000	1,000,000	1990
Hong Kong	1,000,000	1,000,000	1990
Singapore	1,000,000	1,000,000	1990
Malaysia	1,000,000	1,000,000	1990
Indonesia	1,000,000	1,000,000	1990
Philippines	1,000,000	1,000,000	1990
Thailand	1,000,000	1,000,000	1990
Vietnam	1,000,000	1,000,000	1990
Laos	1,000,000	1,000,000	1990
Myanmar	1,000,000	1,000,000	1990
Burma	1,000,000	1,000,000	1990
Cambodia	1,000,000	1,000,000	1990
Sierra Leone	1,000,000	1,000,000	1990
Liberia	1,000,000	1,000,000	1990
Ivory Coast	1,000,000	1,000,000	1990
Ghana	1,000,000	1,000,000	1990
Nigeria	1,000,000	1,000,000	1990
Kenya	1,000,000	1,000,000	1990
Tanzania	1,000,000	1,000,000	1990
Uganda	1,000,000	1,000,000	1990
Rwanda	1,000,000	1,000,000	1990
Burundi	1,000,000	1,000,000	1990
Democratic Republic of Congo	1,000,000	1,000,000	1990
Zambia	1,000,000	1,000,000	1990
Botswana	1,000,000	1,000,000	1990
South Africa	1,000,000	1,000,000	1990
Mozambique	1,000,000	1,000,000	1990
Swaziland	1,000,000	1,000,000	1990
Lesotho	1,000,000	1,000,000	1990
Malawi	1,000,000	1,000,000	1990
Zimbabwe	1,000,000	1,000,000	1990
Angola	1,000,000	1,000,000	1990
Namibia	1,000,000	1,000,000	1990
South West Africa	1,000,000	1,000,000	1990
Swaziland	1,000,000	1,000,000	1990
Botswana	1,000,000	1,000,000	1990
South Africa	1,000,000	1,000,000	1990
Mozambique	1,000,000	1,000,000	1990
Swaziland	1,000,000	1,000,000	1990
Lesotho	1,000,000	1,000,000	1990
Malawi	1,000,000	1,000,000	1990
Zimbabwe	1,000,000	1,000,000	1990
Angola	1,000,000	1,000,000	1990
Namibia	1,000,000	1,000,000	1990
South West Africa	1,000,000	1,000,000	1990
Swaziland	1,000,000	1,000,000	1990
Botswana	1,000,000	1,000,000	1990
South Africa	1,000,000	1,000,000	1990
Mozambique	1,000,000	1,000,000	1990
Swaziland	1,000,000	1,000,000	1990
Lesotho	1,000,000	1,000,000	1990
Malawi	1,000,000	1,000,000	1990
Zimbabwe	1,000,000	1,000,000	1990
Angola	1,000,000	1,000,000	1990
Namibia	1,000,000	1,000,000	1990
South West Africa	1,000,000	1,000,000	1990
Swaziland	1,000,000	1,000,000	1990
Botswana	1,000,000	1,000,000	1990
South Africa	1,000,000	1,000,000	1990
Mozambique	1,000,000	1,000,000	1990
Swaziland	1,000,000	1,000,000	1990
Lesotho	1,000,000	1,000,000	1990
Malawi	1,000,000	1,000,000	1990
Zimbabwe	1,000,000	1	

[illegible][illegible]

the *Journal of the American Medical Association* (JAMA) in 1968, and the *New England Journal of Medicine* in 1970. The *Journal of the American Medical Association* published the first article on the topic of "The Role of the General Practitioner in the Management of the Patient with a Heart Attack" in 1968. The *New England Journal of Medicine* published the first article on the topic of "The Role of the General Practitioner in the Management of the Patient with a Heart Attack" in 1970.

[illegible][illegible]

KAWA, H. 1979. The effect of temperature on the growth of the Japanese flounder, *Paralichthys oblongus* Temm. *Journal of the Japanese Society of Fisheries* 45:103-107.

[illegible][illegible][illegible]

© 2000 by M. J. Griffin, D. J. Whitham, and J. D. M. R. Cantwell. This journal is registered at the Copyright Clearance Center, Inc., 222 Rosewood Drive, Danvers, MA 01923. Organizations in the USA who are also registered with the Copyright Clearance Center may therefore copy material (beyond the limits permitted by sections 107 and 108 of US copyright law) subject to payment to C.C.C. of the per copy fee of \$05.00. This consent does not extend to multiple copying for promotional or commercial purposes. ISI Tear Sheet Service, 3501 Market Street, Philadelphia, PA 19104, USA, is authorized to supply single copies of separate articles for private use only. Organizations authorized by the Copyright Licensing Agency may also copy material subject to the usual conditions. For all other use, permission should be sought from Cambridge or the American Branch of Cambridge University Press.

10. *Journal of the American Statistical Association*, 1997, 92, 1023-1032.

Entity	1997	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026	2027	2028	2029	2030	2031	2032	2033	2034	2035	2036	2037	2038	2039	2040	2041	2042	2043	2044	2045	2046	2047	2048	2049	2050	2051	2052	2053	2054	2055	2056	2057	2058	2059	2060	2061	2062	2063	2064	2065	2066	2067	2068	2069	2070	2071	2072	2073	2074	2075	2076	2077	2078	2079	2080	2081	2082	2083	2084	2085	2086	2087	2088	2089	2090	2091	2092	2093	2094	2095	2096	2097	2098	2099	2100	2101	2102	2103	2104	2105	2106	2107	2108	2109	2110	2111	2112	2113	2114	2115	2116	2117	2118	2119	2120	2121	2122	2123	2124	2125	2126	2127	2128	2129	2130	2131	2132	2133	2134	2135	2136	2137	2138	2139	2140	2141	2142	2143	2144	2145	2146	2147	2148	2149	2150	2151	2152	2153	2154	2155	2156	2157	2158	2159	2160	2161	2162	2163	2164	2165	2166	2167	2168	2169	2170	2171	2172	2173	2174	2175	2176	2177	2178	2179	2180	2181	2182	2183	2184	2185	2186	2187	2188	2189	2190	2191	2192	2193	2194	2195	2196	2197	2198	2199	2200	2201	2202	2203	2204	2205	2206	2207	2208	2209	2210	2211	2212	2213	2214	2215	2216	2217	2218	2219	2220	2221	2222	2223	2224	2225	2226	2227	2228	2229	2230	2231	2232	2233	2234	2235	2236	2237	2238	2239	2240	2241	2242	2243	2244	2245	2246	2247	2248	2249	2250	2251	2252	2253	2254	2255	2256	2257	2258	2259	2260	2261	2262	2263	2264	2265	2266	2267	2268	2269	2270	2271	2272	2273	2274	2275	2276	2277	2278	2279	2280	2281	2282	2283	2284	2285	2286	2287	2288	2289	2290	2291	2292	2293	2294	2295	2296	2297	2298	2299	2300	2301	2302	2303	2304	2305	2306	2307	2308	2309	2310	2311	2312	2313	2314	2315	2316	2317	2318	2319	2320	2321	2322	2323	2324	2325	2326	2327	2328	2329	2330	2331	2332	2333	2334	2335	2336	2337	2338	2339	2340	2341	2342	2343	2344	2345	2346	2347	2348	2349	2350	2351	2352	2353	2354	2355	2356	2357	2358	2359	2360	2361	2362	2363	2364	2365	2366	2367	2368	2369	2370	2371	2372	2373	2374	2375	2376	2377	2378	2379	2380	2381	2382	2383	2384	2385	2386	2387	2388	2389	2390	2391	2392	2393	2394	2395	2396	2397	2398	2399	2400	2401	2402	2403	2404</
--------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	--------

[illegible][illegible]

1. *Exhibitor* – the person or organization that provides the exhibit.  
 2. *Exhibit* – any item or document that is presented as evidence in a trial.  
 3. *Exhibit list* – a list of all the exhibits that are being presented in a trial.  
 4. *Exhibit tag* – a small piece of paper or card that is attached to an exhibit to identify it.  
 5. *Exhibit room* – a room where the exhibits are stored and displayed.  
 6. *Exhibit case* – a container used to hold and protect exhibits.  
 7. *Exhibit label* – a label that is placed on an exhibit to provide information about it.  
 8. *Exhibit log* – a record of all the exhibits that are handled during a trial.  
 9. *Exhibit handling* – the process of moving and displaying exhibits.  
 10. *Exhibit management* – the overall process of organizing and controlling the exhibits.  
 11. *Exhibit storage* – the place where the exhibits are kept when they are not being displayed.  
 12. *Exhibit retrieval* – the process of getting an exhibit out of storage.  
 13. *Exhibit return* – the process of putting an exhibit back into storage.  
 14. *Exhibit security* – the measures taken to protect the exhibits from theft or damage.  
 15. *Exhibit insurance* – insurance coverage for the exhibits.  
 16. *Exhibit photography* – the process of taking pictures of the exhibits.  
 17. *Exhibit video* – a video recording of the exhibits.  
 18. *Exhibit audio* – an audio recording of the exhibits.  
 19. *Exhibit transcription* – a written record of what is said about the exhibits.  
 20. *Exhibit analysis* – the process of examining the exhibits to determine their value.  
 21. *Exhibit valuation* – the process of determining the worth of the exhibits.  
 22. *Exhibit authentication* – the process of proving that the exhibits are what they are claimed to be.  
 23. *Exhibit chain of custody* – a record of all the people who have handled the exhibits.  
 24. *Exhibit preservation* – the process of keeping the exhibits in good condition.  
 25. *Exhibit restoration* – the process of repairing or restoring damaged exhibits.  
 26. *Exhibit conservation* – the process of preventing damage to the exhibits.  
 27. *Exhibit care* – the overall process of looking after the exhibits.  
 28. *Exhibit handling protocol* – a set of rules for how to handle the exhibits.  
 29. *Exhibit handling manual* – a book or guide that explains how to handle the exhibits.  
 30. *Exhibit handling training* – training for people who will be handling the exhibits.  
 31. *Exhibit handling equipment* – the tools and equipment used to handle the exhibits.  
 32. *Exhibit handling supplies* – the materials needed to handle the exhibits.  
 33. *Exhibit handling procedures* – the steps that must be followed when handling the exhibits.  
 34. *Exhibit handling standards* – the rules that must be followed when handling the exhibits.  
 35. *Exhibit handling best practices* – the most effective ways of handling the exhibits.  
 36. *Exhibit handling research* – the study of how to handle the exhibits.  
 37. *Exhibit handling innovation* – new ideas for how to handle the exhibits.  
 38. *Exhibit handling technology* – the use of new tools and equipment to handle the exhibits.  
 39. *Exhibit handling software* – computer programs used to manage the exhibits.  
 40. *Exhibit handling hardware* – the physical equipment used to handle the exhibits.  
 41. *Exhibit handling services* – the professional services provided for handling the exhibits.  
 42. *Exhibit handling consultants* – experts who provide advice on how to handle the exhibits.  
 43. *Exhibit handling contractors* – people who are hired to handle the exhibits.  
 44. *Exhibit handling subcontractors* – people who are hired by a contractor to handle the exhibits.  
 45. *Exhibit handling vendors* – the companies that supply the equipment and materials needed for handling the exhibits.  
 46. *Exhibit handling suppliers* – the companies that provide the services needed for handling the exhibits.  
 47. *Exhibit handling partners* – the companies that work together to handle the exhibits.  
 48. *Exhibit handling alliances* – the formal agreements between companies to handle the exhibits.  
 49. *Exhibit handling networks* – the groups of companies that work together to handle the exhibits.  
 50. *Exhibit handling communities* – the groups of people who are interested in handling the exhibits.  
 51. *Exhibit handling associations* – the organizations that represent the people who handle the exhibits.  
 52. *Exhibit handling societies* – the groups of people who share a common interest in handling the exhibits.  
 53. *Exhibit handling clubs* – the groups of people who meet regularly to discuss handling the exhibits.  
 54. *Exhibit handling groups* – the groups of people who work together to handle the exhibits.  
 55. *Exhibit handling teams* – the groups of people who are responsible for handling the exhibits.  
 56. *Exhibit handling departments* – the parts of an organization that handle the exhibits.  
 57. *Exhibit handling divisions* – the parts of an organization that handle the exhibits.  
 58. *Exhibit handling units* – the parts of an organization that handle the exhibits.  
 59. *Exhibit handling sections* – the parts of an organization that handle the exhibits.  
 60. *Exhibit handling offices* – the places where the people who handle the exhibits work.  
 61. *Exhibit handling centers* – the places where the people who handle the exhibits work.  
 62. *Exhibit handling facilities* – the places where the people who handle the exhibits work.  
 63. *Exhibit handling locations* – the places where the people who handle the exhibits work.  
 64. *Exhibit handling sites* – the places where the people who handle the exhibits work.  
 65. *Exhibit handling venues* – the places where the people who handle the exhibits work.  
 66. *Exhibit handling spaces* – the places where the people who handle the exhibits work.  
 67. *Exhibit handling areas* – the places where the people who handle the exhibits work.  
 68. *Exhibit handling zones* – the places where the people who handle the exhibits work.  
 69. *Exhibit handling regions* – the places where the people who handle the exhibits work.  
 70. *Exhibit handling territories* – the places where the people who handle the exhibits work.  
 71. *Exhibit handling jurisdictions* – the places where the people who handle the exhibits work.  
 72. *Exhibit handling domains* – the places where the people who handle the exhibits work.  
 73. *Exhibit handling spheres* – the places where the people who handle the exhibits work.  
 74. *Exhibit handling circles* – the places where the people who handle the exhibits work.  
 75. *Exhibit handling rings* – the places where the people who handle the exhibits work.  
 76. *Exhibit handling bands* – the places where the people who handle the exhibits work.  
 77. *Exhibit handling layers* – the places where the people who handle the exhibits work.  
 78. *Exhibit handling levels* – the places where the people who handle the exhibits work.  
 79. *Exhibit handling ranks* – the places where the people who handle the exhibits work.  
 80. *Exhibit handling grades* – the places where the people who handle the exhibits work.  
 81. *Exhibit handling classes* – the places where the people who handle the exhibits work.  
 82. *Exhibit handling orders* – the places where the people who handle the exhibits work.  
 83. *Exhibit handling degrees* – the places where the people who handle the exhibits work.  
 84. *Exhibit handling titles* – the places where the people who handle the exhibits work.  
 85. *Exhibit handling positions* – the places where the people who handle the exhibits work.  
 86. *Exhibit handling roles* – the places where the people who handle the exhibits work.  
 87. *Exhibit handling responsibilities* – the places where the people who handle the exhibits work.  
 88. *Exhibit handling duties* – the places where the people who handle the exhibits work.  
 89. *Exhibit handling tasks* – the places where the people who handle the exhibits work.  
 90. *Exhibit handling jobs* – the places where the people who handle the exhibits work.  
 91. *Exhibit handling careers* – the places where the people who handle the exhibits work.  
 92. *Exhibit handling professions* – the places where the people who handle the exhibits work.  
 93. *Exhibit handling vocations* – the places where the people who handle the exhibits work.  
 94. *Exhibit handling occupations* – the places where the people who handle the exhibits work.  
 95. *Exhibit handling trades* – the places where the people who handle the exhibits work.  
 96. *Exhibit handling crafts* – the places where the people who handle the exhibits work.  
 97. *Exhibit handling arts* – the places where the people who handle the exhibits work.  
 98. *Exhibit handling sciences* – the places where the people who handle the exhibits work.  
 99. *Exhibit handling professions* – the places where the people who handle the exhibits work.  
 100. *Exhibit handling vocations* – the places where the people who handle the exhibits work.

Run	Time	Temp	Pressure	Flow	Conc	Yield	Product
1	10 min	100°C	100 mmHg	10 ml/min	0.1 M	0.1 g	100%
2	20 min	100°C	100 mmHg	10 ml/min	0.1 M	0.2 g	100%
3	30 min	100°C	100 mmHg	10 ml/min	0.1 M	0.3 g	100%
4	40 min	100°C	100 mmHg	10 ml/min	0.1 M	0.4 g	100%
5	50 min	100°C	100 mmHg	10 ml/min	0.1 M	0.5 g	100%
6	60 min	100°C	100 mmHg	10 ml/min	0.1 M	0.6 g	100%
7	70 min	100°C	100 mmHg	10 ml/min	0.1 M	0.7 g	100%
8	80 min	100°C	100 mmHg	10 ml/min	0.1 M	0.8 g	100%
9	90 min	100°C	100 mmHg	10 ml/min	0.1 M	0.9 g	100%
10	100 min	100°C	100 mmHg	10 ml/min	0.1 M	1.0 g	100%

Country	Method	Year	Source	Accession	Number of Isolated Strains	Number of Identified Strains	Number of Antigenic Variants
France	Random	1989	1	1	1	1	0
France	Random	1990	1	1	1	1	0
France	Random	1991	1	1	1	1	0
France	Random	1992	1	1	1	1	0
France	Random	1993	1	1	1	1	0
France	Random	1994	1	1	1	1	0
France	Random	1995	1	1	1	1	0
France	Random	1996	1	1	1	1	0
France	Random	1997	1	1	1	1	0
France	Random	1998	1	1	1	1	0
France	Random	1999	1	1	1	1	0
France	Random	2000	1	1	1	1	0
France	Random	2001	1	1	1	1	0
France	Random	2002	1	1	1	1	0
France	Random	2003	1	1	1	1	0
France	Random	2004	1	1	1	1	0
France	Random	2005	1	1	1	1	0
France	Random	2006	1	1	1	1	0
France	Random	2007	1	1	1	1	0
France	Random	2008	1	1	1	1	0
France	Random	2009	1	1	1	1	0
France	Random	2010	1	1	1	1	0
France	Random	2011	1	1	1	1	0
France	Random	2012	1	1	1	1	0
France	Random	2013	1	1	1	1	0
France	Random	2014	1	1	1	1	0
France	Random	2015	1	1	1	1	0
France	Random	2016	1	1	1	1	0
France	Random	2017	1	1	1	1	0
France	Random	2018	1	1	1	1	0
France	Random	2019	1	1	1	1	0
France	Random	2020	1	1	1	1	0
France	Random	2021	1	1	1	1	0
France	Random	2022	1	1	1	1	0
France	Random	2023	1	1	1	1	0
France	Random	2024	1	1	1	1	0
France	Random	2025	1	1	1	1	0
France	Random	2026	1	1	1	1	0
France	Random	2027	1	1	1	1	0
France	Random	2028	1	1	1	1	0
France	Random	2029	1	1	1	1	0
France	Random	2030	1	1	1	1	0
France	Random	2031	1	1	1	1	0
France	Random	2032	1	1	1	1	0
France	Random	2033	1	1	1	1	0
France	Random	2034	1	1	1	1	0
France	Random	2035	1	1	1	1	0
France	Random	2036	1	1	1	1	0
France	Random	2037	1	1	1	1	0
France	Random	2038	1	1	1	1	0
France	Random	2039	1	1	1	1	0
France	Random	2040	1	1	1	1	0
France	Random	2041	1	1	1	1	0
France	Random	2042	1	1	1	1	0
France	Random	2043	1	1	1	1	0
France	Random	2044	1	1	1	1	0
France	Random	2045	1	1	1	1	0
France	Random	2046	1	1	1	1	0
France	Random	2047	1	1	1	1	0
France	Random	2048	1	1	1	1	0
France	Random	2049					

[illegible][illegible]

ALLEN, J. D., and J. D. ALLEN. 1979. The effects of temperature and salinity on the growth and survival of the bay anchovy, *Anchoa hepsetus*, in the Chesapeake Bay. *Journal of Experimental Marine Biology and Ecology* 129:1-15.

RECEIVED BY THE  
AUTHOR(S)  
TITLE  
JOURNAL  
MONTH AND  
YEAR

[illegible]

Query Match 60.08% Score 127 108 62 Length 300  
 Local Similarity 75.08% Pred. No. 90004  
 Matches 17 Conserved 02 Mismatches 15 Indels 02 Gaps 02

Query Match 60.08% Score 127 108 62 Length 300  
 Local Similarity 75.08% Pred. No. 90004  
 Matches 17 Conserved 02 Mismatches 15 Indels 02 Gaps 02

Query Match 60.08% Score 127 108 62 Length 300  
 Local Similarity 75.08% Pred. No. 90004  
 Matches 17 Conserved 02 Mismatches 15 Indels 02 Gaps 02

Query Match 60.08% Score 127 108 62 Length 300  
 Local Similarity 75.08% Pred. No. 90004  
 Matches 17 Conserved 02 Mismatches 15 Indels 02 Gaps 02

Query Match 60.08% Score 127 108 62 Length 300  
 Local Similarity 75.08% Pred. No. 90004  
 Matches 17 Conserved 02 Mismatches 15 Indels 02 Gaps 02

Query Match 60.08% Score 127 108 62 Length 300  
 Local Similarity 75.08% Pred. No. 90004  
 Matches 17 Conserved 02 Mismatches 15 Indels 02 Gaps 02

Query Match 60.08% Score 127 108 62 Length 300  
 Local Similarity 75.08% Pred. No. 90004  
 Matches 17 Conserved 02 Mismatches 15 Indels 02 Gaps 02

Query Match 60.08% Score 127 108 62 Length 300  
 Local Similarity 75.08% Pred. No. 90004  
 Matches 17 Conserved 02 Mismatches 15 Indels 02 Gaps 02

Query Match 60.08% Score 127 108 62 Length 300  
 Local Similarity 75.08% Pred. No. 90004  
 Matches 17 Conserved 02 Mismatches 15 Indels 02 Gaps 02

REFERENCE 1 (bases 1 to 300)  
 AUTHORS Matsumoto, S.K., George, A.L., Jr., and Nuzarekko, L.  
 TITLE Amplification of nucleic acid sequences  
 JOURNAL Patient: US 5598940 A 7 14 JAN 1997  
 FEATURES Location/Qualifiers  
 SOURCE L. 300  
 ORGANISM "unknown"  
 ORIGIN 5' 3' 12 1

Query Match 60.08% Score 127 108 62 Length 300  
 Local Similarity 75.08% Pred. No. 90004  
 Matches 17 Conserved 02 Mismatches 15 Indels 02 Gaps 02

Query Match 60.08% Score 127 108 62 Length 300  
 Local Similarity 75.08% Pred. No. 90004  
 Matches 17 Conserved 02 Mismatches 15 Indels 02 Gaps 02

Query Match 60.08% Score 127 108 62 Length 300  
 Local Similarity 75.08% Pred. No. 90004  
 Matches 17 Conserved 02 Mismatches 15 Indels 02 Gaps 02

Query Match 60.08% Score 127 108 62 Length 300  
 Local Similarity 75.08% Pred. No. 90004  
 Matches 17 Conserved 02 Mismatches 15 Indels 02 Gaps 02

Query Match 60.08% Score 127 108 62 Length 300  
 Local Similarity 75.08% Pred. No. 90004  
 Matches 17 Conserved 02 Mismatches 15 Indels 02 Gaps 02

Query Match 60.08% Score 127 108 62 Length 300  
 Local Similarity 75.08% Pred. No. 90004  
 Matches 17 Conserved 02 Mismatches 15 Indels 02 Gaps 02

Query Match 60.08% Score 127 108 62 Length 300  
 Local Similarity 75.08% Pred. No. 90004  
 Matches 17 Conserved 02 Mismatches 15 Indels 02 Gaps 02













19. *Leptochloa* (L.) Boeckl. (*Leptochloa*)  
 19. *Leptochloa* (L.) Boeckl. (*Leptochloa*)  
 19. *Leptochloa* (L.) Boeckl. (*Leptochloa*)

the growth of the  $\text{Fe}_2\text{O}_3$  film, and the  $\text{Fe}_2\text{O}_3$  film thickness was 20–50 nm. The  $\text{Fe}_2\text{O}_3$  film was prepared by the following procedure:

[illegible]

**KEYWORDS:** plasma; plasma frequency; electron density; ionosphere; ionospheric modification

$$\begin{aligned} & \frac{1}{\Gamma} = \frac{1}{\Gamma_0} + \frac{1}{\Gamma_1} \\ & \frac{1}{\Gamma_0} = \frac{1}{\Gamma_0} + \frac{1}{\Gamma_1} \\ & \frac{1}{\Gamma_1} = \frac{1}{\Gamma_0} + \frac{1}{\Gamma_1} \\ & \frac{1}{\Gamma_2} = \frac{1}{\Gamma_0} + \frac{1}{\Gamma_1} + \frac{1}{\Gamma_2} \\ & \frac{1}{\Gamma_3} = \frac{1}{\Gamma_0} + \frac{1}{\Gamma_1} + \frac{1}{\Gamma_2} + \frac{1}{\Gamma_3} \\ & \frac{1}{\Gamma_4} = \frac{1}{\Gamma_0} + \frac{1}{\Gamma_1} + \frac{1}{\Gamma_2} + \frac{1}{\Gamma_3} + \frac{1}{\Gamma_4} \\ & \frac{1}{\Gamma_5} = \frac{1}{\Gamma_0} + \frac{1}{\Gamma_1} + \frac{1}{\Gamma_2} + \frac{1}{\Gamma_3} + \frac{1}{\Gamma_4} + \frac{1}{\Gamma_5} \\ & \frac{1}{\Gamma_6} = \frac{1}{\Gamma_0} + \frac{1}{\Gamma_1} + \frac{1}{\Gamma_2} + \frac{1}{\Gamma_3} + \frac{1}{\Gamma_4} + \frac{1}{\Gamma_5} + \frac{1}{\Gamma_6} \\ & \frac{1}{\Gamma_7} = \frac{1}{\Gamma_0} + \frac{1}{\Gamma_1} + \frac{1}{\Gamma_2} + \frac{1}{\Gamma_3} + \frac{1}{\Gamma_4} + \frac{1}{\Gamma_5} + \frac{1}{\Gamma_6} + \frac{1}{\Gamma_7} \\ & \frac{1}{\Gamma_8} = \frac{1}{\Gamma_0} + \frac{1}{\Gamma_1} + \frac{1}{\Gamma_2} + \frac{1}{\Gamma_3} + \frac{1}{\Gamma_4} + \frac{1}{\Gamma_5} + \frac{1}{\Gamma_6} + \frac{1}{\Gamma_7} + \frac{1}{\Gamma_8} \\ & \frac{1}{\Gamma_9} = \frac{1}{\Gamma_0} + \frac{1}{\Gamma_1} + \frac{1}{\Gamma_2} + \frac{1}{\Gamma_3} + \frac{1}{\Gamma_4} + \frac{1}{\Gamma_5} + \frac{1}{\Gamma_6} + \frac{1}{\Gamma_7} + \frac{1}{\Gamma_8} + \frac{1}{\Gamma_9} \\ & \frac{1}{\Gamma_{10}} = \frac{1}{\Gamma_0} + \frac{1}{\Gamma_1} + \frac{1}{\Gamma_2} + \frac{1}{\Gamma_3} + \frac{1}{\Gamma_4} + \frac{1}{\Gamma_5} + \frac{1}{\Gamma_6} + \frac{1}{\Gamma_7} + \frac{1}{\Gamma_8} + \frac{1}{\Gamma_9} + \frac{1}{\Gamma_{10}} \end{aligned}$$
[illegible][illegible]

and polyacrylamide gels. The DNA was hydroxymethylated by repeated passage through a 0.005-inch orifice at constant velocity. The sheared DNA was blunt end-repaired with T4 DNA polymerase and T4

polymerization. A 10-fold molar excess of monomer was added to the blunt ends in high molar excess. The adaptor DNA was purified and size-selected for a 9.5 to 19.5 kb range using preparative agarose gel.

vector, respectively. Vector *l* was prepared from a cDNA library of pMOL2 (G1474214) (pM2.07.2.), a copy-number imbalanced derivative of plasmid R1. The vector was ligated with adaptors complementary to the insert adaptors and

portion, the *Shigella* adaptation mouse DNA was annealing to a bacteriophage  $\lambda$  vector, and transformed into chemically competent *E. coli* XL10 Gold (Stratagene) cells and selected for ampicillin resistance.<sup>16</sup>

Letter frequency	61.0%	Score	1.2e-27	DB	13	Length	38
Local lexical similarity	82.4%	Prod. No.	1.2e-05				
Markers	14	Consonants	6	Labels	0	Gaps	0

[illegible][illegible]

1. **INTRODUCTION**  
 2. **EXPERIMENTAL**  
 3. **RESULTS AND DISCUSSION**  
 4. **CONCLUSIONS**  
 5. **REFERENCES**  
 6. **APPENDIX**  
 7. **ACKNOWLEDGMENTS**  
 8. **NOTES**  
 9. **REFERENCES**  
 10. **APPENDIX**  
 11. **ACKNOWLEDGMENTS**  
 12. **NOTES**  
 13. **REFERENCES**  
 14. **APPENDIX**  
 15. **ACKNOWLEDGMENTS**  
 16. **NOTES**  
 17. **REFERENCES**  
 18. **APPENDIX**  
 19. **ACKNOWLEDGMENTS**  
 20. **NOTES**  
 21. **REFERENCES**  
 22. **APPENDIX**  
 23. **ACKNOWLEDGMENTS**  
 24. **NOTES**  
 25. **REFERENCES**  
 26. **APPENDIX**  
 27. **ACKNOWLEDGMENTS**  
 28. **NOTES**  
 29. **REFERENCES**  
 30. **APPENDIX**  
 31. **ACKNOWLEDGMENTS**  
 32. **NOTES**  
 33. **REFERENCES**  
 34. **APPENDIX**  
 35. **ACKNOWLEDGMENTS**  
 36. **NOTES**  
 37. **REFERENCES**  
 38. **APPENDIX**  
 39. **ACKNOWLEDGMENTS**  
 40. **NOTES**  
 41. **REFERENCES**  
 42. **APPENDIX**  
 43. **ACKNOWLEDGMENTS**  
 44. **NOTES**  
 45. **REFERENCES**  
 46. **APPENDIX**  
 47. **ACKNOWLEDGMENTS**  
 48. **NOTES**  
 49. **REFERENCES**  
 50. **APPENDIX**  
 51. **ACKNOWLEDGMENTS**  
 52. **NOTES**  
 53. **REFERENCES**  
 54. **APPENDIX**  
 55. **ACKNOWLEDGMENTS**  
 56. **NOTES**  
 57. **REFERENCES**  
 58. **APPENDIX**  
 59. **ACKNOWLEDGMENTS**  
 60. **NOTES**  
 61. **REFERENCES**  
 62. **APPENDIX**  
 63. **ACKNOWLEDGMENTS**  
 64. **NOTES**  
 65. **REFERENCES**  
 66. **APPENDIX**  
 67. **ACKNOWLEDGMENTS**  
 68. **NOTES**  
 69. **REFERENCES**  
 70. **APPENDIX**  
 71. **ACKNOWLEDGMENTS**  
 72. **NOTES**  
 73. **REFERENCES**  
 74. **APPENDIX**  
 75. **ACKNOWLEDGMENTS**  
 76. **NOTES**  
 77. **REFERENCES**  
 78. **APPENDIX**  
 79. **ACKNOWLEDGMENTS**  
 80. **NOTES**  
 81. **REFERENCES**  
 82. **APPENDIX**  
 83. **ACKNOWLEDGMENTS**  
 84. **NOTES**  
 85. **REFERENCES**  
 86. **APPENDIX**  
 87. **ACKNOWLEDGMENTS**  
 88. **NOTES**  
 89. **REFERENCES**  
 90. **APPENDIX**  
 91. **ACKNOWLEDGMENTS**  
 92. **NOTES**  
 93. **REFERENCES**  
 94. **APPENDIX**  
 95. **ACKNOWLEDGMENTS**  
 96. **NOTES**  
 97. **REFERENCES**  
 98. **APPENDIX**  
 99. **ACKNOWLEDGMENTS**  
 100. **NOTES**  
 101. **REFERENCES**  
 102. **APPENDIX**  
 103. **ACKNOWLEDGMENTS**  
 104. **NOTES**  
 105. **REFERENCES**  
 106. **APPENDIX**  
 107. **ACKNOWLEDGMENTS**  
 108. **NOTES**  
 109. **REFERENCES**  
 110. **APPENDIX**  
 111. **ACKNOWLEDGMENTS**  
 112. **NOTES**  
 113. **REFERENCES**  
 114. **APPENDIX**  
 115. **ACKNOWLEDGMENTS**  
 116. **NOTES**  
 117. **REFERENCES**  
 118. **APPENDIX**  
 119. **ACKNOWLEDGMENTS**  
 120. **NOTES**  
 121. **REFERENCES**  
 122. **APPENDIX**  
 123. **ACKNOWLEDGMENTS**  
 124. **NOTES**  
 125. **REFERENCES**  
 126. **APPENDIX**  
 127. **ACKNOWLEDGMENTS**  
 128. **NOTES**  
 129. **REFERENCES**  
 130. **APPENDIX**  
 131. **ACKNOWLEDGMENTS**  
 132. **NOTES**  
 133. **REFERENCES**  
 134. **APPENDIX**  
 135. **ACKNOWLEDGMENTS**  
 136. **NOTES**  
 137. **REFERENCES**  
 138. **APPENDIX**  
 139. **ACKNOWLEDGMENTS**  
 140. **NOTES**  
 141. **REFERENCES**  
 142. **APPENDIX**  
 143. **ACKNOWLEDGMENTS**  
 144. **NOTES**  
 145. **REFERENCES**  
 146. **APPENDIX**  
 147. **ACKNOWLEDGMENTS**  
 148. **NOTES**  
 149. **REFERENCES**  
 150. **APPENDIX**  
 151. **ACKNOWLEDGMENTS**  
 152. **NOTES**  
 153. **REFERENCES**  
 154. **APPENDIX**  
 155. **ACKNOWLEDGMENTS**  
 156. **NOTES**  
 157. **REFERENCES**  
 158. **APPENDIX**  
 159. **ACKNOWLEDGMENTS**  
 160. **NOTES**  
 161. **REFERENCES**  
 162. **APPENDIX**  
 163. **ACKNOWLEDGMENTS**  
 164. **NOTES**  
 165. **REFERENCES**  
 166. **APPENDIX**  
 167. **ACKNOWLEDGMENTS**  
 168. **NOTES**  
 169. **REFERENCES**  
 170. **APPENDIX**  
 171. **ACKNOWLEDGMENTS**  
 172. **NOTES**  
 173. **REFERENCES**  
 174. **APPENDIX**  
 175. **ACKNOWLEDGMENTS**  
 176. **NOTES**  
 177. **REFERENCES**  
 178. **APPENDIX**  
 179. **ACKNOWLEDGMENTS**  
 180. **NOTES**  
 181. **REFERENCES**  
 182. **APPENDIX**  
 183. **ACKNOWLEDGMENTS**  
 184. **NOTES**  
 185. **REFERENCES**  
 186. **APPENDIX**  
 187. **ACKNOWLEDGMENTS**  
 188. **NOTES**  
 189. **REFERENCES**  
 190. **APPENDIX**  
 191. **ACKNOWLEDGMENTS**  
 192. **NOTES**  
 193. **REFERENCES**  
 194. **APPENDIX**  
 195. **ACKNOWLEDGMENTS**  
 196. **NOTES**  
 197. **REFERENCES**  
 198. **APPENDIX**  
 199. **ACKNOWLEDGMENTS**  
 200. **NOTES**  
 201. **REFERENCES**  
 202. **APPENDIX**  
 203. **ACKNOWLEDGMENTS**  
 204. **NOTES**  
 205. **REFERENCES**  
 206. **APPENDIX**  
 207. **ACKNOWLEDGMENTS**  
 208. **NOTES**  
 209. **REFERENCES**  
 210. **APPENDIX**  
 211. **ACKNOWLEDGMENTS**  
 212. **NOTES**  
 213. **REFERENCES**  
 214. **APPENDIX**  
 215. **ACKNOWLEDGMENTS**  
 216. **NOTES**  
 217. **REFERENCES**  
 218. **APPENDIX**  
 219. **ACKNOWLEDGMENTS**  
 220. **NOTES**  
 221. **REFERENCES**  
 222. **APPENDIX**  
 223. **ACKNOWLEDGMENTS**  
 224. **NOTES**  
 225. **REFERENCES**  
 226. **APPENDIX**  
 227. **ACKNOWLEDGMENTS**  
 228. **NOTES**  
 229. **REFERENCES**  
 230. **APPENDIX**  
 231. **ACKNOWLEDGMENTS**  
 232. **NOTES**  
 233. **REFERENCES**  
 234. **APPENDIX**  
 235. **ACKNOWLEDGMENTS**  
 236. **NOTES**  
 237. **REFERENCES**  
 238. **APPENDIX**  
 239. **ACKNOWLEDGMENTS**  
 240. **NOTES**<

[illegible]

Enkripsiya: Metazoon; Chordata; Chordata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus. (bassini 1 To 43)

Reichel, S., Kumbauld, J., Jay, M., La'Mo, M., Marshall, M., Morris, M., Nephel-Loebach, K., Stephens, M., John, F., Underwood, K., Basso, H., Theobald, B., Wyllie, L., Lammont, G., Soares, B., Wilson, K., and

Waterston, R.	Waterston, R.
Little Johnston Camp/2017	Little Johnston Camp/2017
Inputted (1900)	Inputted (1900)
Output - Little Mouse EST Project	Output - Little Mouse EST Project

Washburn Memorial East Project  
Washington University School of Medicine, Box  
4444 Forest Park Parkway, Box 8501, St. Louis, MO 63110  
Tel.: 314-286-1800

Fax: 414 286 1810  
Email: [theoffice@wsl.com](mailto:theoffice@wsl.com)  
This is where I'd advise taking a copy of the "2004-2005" FARMER'S GUIDE from the following link for further information:

### Motivation

Trade consists of several good quality products. I've spent a lot of money on what should be a good quality product.

With equality of opportunity, the  
 FERTILITY  
 SURFACE

[illegible]
$$\frac{\text{Zhou\_stage\_m13.5\_14\_tdpc\_total\_trials}^n}{\text{Zhou\_stage\_m13.5\_14\_tdpc\_total\_trials}^n} \times \frac{\text{Zhou\_stage\_m13.5\_14\_tdpc\_total\_trials}^n}{\text{Zhou\_stage\_m13.5\_14\_tdpc\_total\_trials}^n}$$

Photoemission spectroscopy (Pharmacia) with a modified polyimide-coated Si(111) surface. The Si(111) surface was primed with a Not (1-ethoxy(4-ethyl)pyrrolidyl) primer [19].

14. *Exogenous total RNA provided by Michael K. Wiegman, State Univ., from 2-1; double-stranded cDNA was inserted to*

to RTase (reverse transcriptase) activity was amplified into the Not I and Eco RI sites of the modified pTZ19 vector. Libraries were through one round of normalization, and was constructed by Ben-to-Siames and

	Methylolacrylate,	
BASIC CATALYST	1) a	1)
CORRECTION	14 c	7 d

Utility Match	61.0%	Score (z,z)	(08,1)	Length	4	
Best Local Similarity	82.4%	Freq. No.	1,40005			
Matches	147	Characters	4	Indices	10	295

[illegible]

## RESULT 10

[illegible]

Version  
Keywords  
Software  
Organization  
Mus. Inscruits  
Comments

**REFERENCES**

Jain D., Nayak A., Barber M., Wadhvani J., Payal P., Hamed A.,  
Pankajodai, Metazon; Choudhari; Verghese; Gupta; Singh;  
Munimath; Dutta; Kulkarni; Sridharan; Murthy; Mats  
1 (pages 1 to 43)

**AUTHORS**

1171 F. Islam, H., Iannace, S., Mahmood, M., Mouton, F., Pop-Escu, J., Kelly, M., Koso, M., Koso, K., Stokes, R., Timpby, A., Van Meterhausen, A., and Wright, D., Weiss, R.

PLASMAID INSECTS  
JOURNAL,  
Unpublished (2000)



1. 1000  
 2. 1000  
 3. 1000  
 4. 1000  
 5. 1000  
 6. 1000  
 7. 1000  
 8. 1000  
 9. 1000  
 10. 1000  
 11. 1000  
 12. 1000  
 13. 1000  
 14. 1000  
 15. 1000  
 16. 1000  
 17. 1000  
 18. 1000  
 19. 1000  
 20. 1000  
 21. 1000  
 22. 1000  
 23. 1000  
 24. 1000  
 25. 1000  
 26. 1000  
 27. 1000  
 28. 1000  
 29. 1000  
 30. 1000  
 31. 1000  
 32. 1000  
 33. 1000  
 34. 1000  
 35. 1000  
 36. 1000  
 37. 1000  
 38. 1000  
 39. 1000  
 40. 1000  
 41. 1000  
 42. 1000  
 43. 1000  
 44. 1000  
 45. 1000  
 46. 1000  
 47. 1000  
 48. 1000  
 49. 1000  
 50. 1000  
 51. 1000  
 52. 1000  
 53. 1000  
 54. 1000  
 55. 1000  
 56. 1000  
 57. 1000  
 58. 1000  
 59. 1000  
 60. 1000  
 61. 1000  
 62. 1000  
 63. 1000  
 64. 1000  
 65. 1000  
 66. 1000  
 67. 1000  
 68. 1000  
 69. 1000  
 70. 1000  
 71. 1000  
 72. 1000  
 73. 1000  
 74. 1000  
 75. 1000  
 76. 1000  
 77. 1000  
 78. 1000  
 79. 1000  
 80. 1000  
 81. 1000  
 82. 1000  
 83. 1000  
 84. 1000  
 85. 1000  
 86. 1000  
 87. 1000  
 88. 1000  
 89. 1000  
 90. 1000  
 91. 1000  
 92. 1000  
 93. 1000  
 94. 1000  
 95. 1000  
 96. 1000  
 97. 1000  
 98. 1000  
 99. 1000  
 100. 1000





Mon Feb 11 09:19:43 2002

us-10-006-430-49.szlm60.rst

Page 9






Figure 1. The effect of the concentration of the *Agaricus bisporus* spores on the growth of *Agaricus bisporus* on the substrate. The concentration of the spores was 10<sup>4</sup> spores/g (a), 10<sup>5</sup> spores/g (b), 10<sup>6</sup> spores/g (c), 10<sup>7</sup> spores/g (d), 10<sup>8</sup> spores/g (e), 10<sup>9</sup> spores/g (f), 10<sup>10</sup> spores/g (g), 10<sup>11</sup> spores/g (h), 10<sup>12</sup> spores/g (i), 10<sup>13</sup> spores/g (j), 10<sup>14</sup> spores/g (k), 10<sup>15</sup> spores/g (l), 10<sup>16</sup> spores/g (m), 10<sup>17</sup> spores/g (n), 10<sup>18</sup> spores/g (o), 10<sup>19</sup> spores/g (p), 10<sup>20</sup> spores/g (q), 10<sup>21</sup> spores/g (r), 10<sup>22</sup> spores/g (s), 10<sup>23</sup> spores/g (t), 10<sup>24</sup> spores/g (u), 10<sup>25</sup> spores/g (v), 10<sup>26</sup> spores/g (w), 10<sup>27</sup> spores/g (x), 10<sup>28</sup> spores/g (y), 10<sup>29</sup> spores/g (z), 10<sup>30</sup> spores/g (aa), 10<sup>31</sup> spores/g (ab), 10<sup>32</sup> spores/g (ac), 10<sup>33</sup> spores/g (ad), 10<sup>34</sup> spores/g (ae), 10<sup>35</sup> spores/g (af), 10<sup>36</sup> spores/g (ag), 10<sup>37</sup> spores/g (ah), 10<sup>38</sup> spores/g (ai), 10<sup>39</sup> spores/g (aj), 10<sup>40</sup> spores/g (ak), 10<sup>41</sup> spores/g (al), 10<sup>42</sup> spores/g (am), 10<sup>43</sup> spores/g (an), 10<sup>44</sup> spores/g (ao), 10<sup>45</sup> spores/g (ap), 10<sup>46</sup> spores/g (aq), 10<sup>47</sup> spores/g (ar), 10<sup>48</sup> spores/g (as), 10<sup>49</sup> spores/g (at), 10<sup>50</sup> spores/g (au), 10<sup>51</sup> spores/g (av), 10<sup>52</sup> spores/g (aw), 10<sup>53</sup> spores/g (ax), 10<sup>54</sup> spores/g (ay), 10<sup>55</sup> spores/g (az), 10<sup>56</sup> spores/g (ba), 10<sup>57</sup> spores/g (bb), 10<sup>58</sup> spores/g (bc), 10<sup>59</sup> spores/g (bd), 10<sup>60</sup> spores/g (be), 10<sup>61</sup> spores/g (bf), 10<sup>62</sup> spores/g (bg), 10<sup>63</sup> spores/g (bh), 10<sup>64</sup> spores/g (bi), 10<sup>65</sup> spores/g (bj), 10<sup>66</sup> spores/g (bk), 10<sup>67</sup> spores/g (bl), 10<sup>68</sup> spores/g (bm), 10<sup>69</sup> spores/g (bn), 10<sup>70</sup> spores/g (bo), 10<sup>71</sup> spores/g (bp), 10<sup>72</sup> spores/g (bq), 10<sup>73</sup> spores/g (br), 10<sup>74</sup> spores/g (bs), 10<sup>75</sup> spores/g (bt), 10<sup>76</sup> spores/g (bu), 10<sup>77</sup> spores/g (bv), 10<sup>78</sup> spores/g (bw), 10<sup>79</sup> spores/g (bx), 10<sup>80</sup> spores/g (by), 10<sup>81</sup> spores/g (bz), 10<sup>82</sup> spores/g (ca), 10<sup>83</sup> spores/g (cb), 10<sup>84</sup> spores/g (cc), 10<sup>85</sup> spores/g (cd), 10<sup>86</sup> spores/g (ce), 10<sup>87</sup> spores/g (cf), 10<sup>88</sup> spores/g (cg), 10<sup>89</sup> spores/g (ch), 10<sup>90</sup> spores/g (ci), 10<sup>91</sup> spores/g (cj), 10<sup>92</sup> spores/g (ck), 10<sup>93</sup> spores/g (cl), 10<sup>94</sup> spores/g (cm), 10<sup>95</sup> spores/g (cn), 10<sup>96</sup> spores/g (co), 10<sup>97</sup> spores/g (cp), 10<sup>98</sup> spores/g (cq), 10<sup>99</sup> spores/g (cr), 10<sup>100</sup> spores/g (cs), 10<sup>101</sup> spores/g (ct), 10<sup>102</sup> spores/g (cu), 10<sup>103</sup> spores/g (cv), 10<sup>104</sup> spores/g (cw), 10<sup>105</sup> spores/g (cx), 10<sup>106</sup> spores/g (cy), 10<sup>107</sup> spores/g (cz), 10<sup>108</sup> spores/g (da), 10<sup>109</sup> spores/g (db), 10<sup>110</sup> spores/g (dc), 10<sup>111</sup> spores/g (dd), 10<sup>112</sup> spores/g (de), 10<sup>113</sup> spores/g (df), 10<sup>114</sup> spores/g (dg), 10<sup>115</sup> spores/g (dh), 10<sup>116</sup> spores/g (di), 10<sup>117</sup> spores/g (dj), 10<sup>118</sup> spores/g (dk), 10<sup>119</sup> spores/g (dl), 10<sup>120</sup> spores/g (dm), 10<sup>121</sup> spores/g (dn), 10<sup>122</sup> spores/g (do), 10<sup>123</sup> spores/g (dp), 10<sup>124</sup> spores/g (dq), 10<sup>125</sup> spores/g (dr), 10<sup>126</sup> spores/g (ds), 10<sup>127</sup> spores/g (dt), 10<sup>128</sup> spores/g (du), 10<sup>129</sup> spores/g (dv), 10<sup>130</sup> spores/g (dw), 10<sup>131</sup> spores/g (dx), 10<sup>132</sup> spores/g (dy), 10<sup>133</sup> spores/g (dz), 10<sup>134</sup> spores/g (ea), 10<sup>135</sup> spores/g (eb), 10<sup>136</sup> spores/g (ec), 10<sup>137</sup> spores/g (ed), 10<sup>138</sup> spores/g (ee), 10<sup>139</sup> spores/g (ef), 10<sup>140</sup> spores/g (eg), 10<sup>141</sup> spores/g (eh), 10<sup>142</sup> spores/g (ei), 10<sup>143</sup> spores/g (ej), 10<sup>144</sup> spores/g (ek), 10<sup>145</sup> spores/g (el), 10<sup>146</sup> spores/g (em), 10<sup>147</sup> spores/g (en), 10<sup>148</sup> spores/g (eo), 10<sup>149</sup> spores/g (ep), 10<sup>150</sup> spores/g (eq), 10<sup>151</sup> spores/g (er), 10<sup>152</sup> spores/g (es), 10<sup>153</sup> spores/g (et), 10<sup>154</sup> spores/g (eu), 10<sup>155</sup> spores/g (ev), 10<sup>156</sup> spores/g (ew), 10<sup>157</sup> spores/g (ex), 10<sup>158</sup> spores/g (ey), 10<sup>159</sup> spores/g (ez), 10<sup>160</sup> spores/g (fa), 10<sup>161</sup> spores/g (fb), 10<sup>162</sup> spores/g (fc), 10<sup>163</sup> spores/g (fd), 10<sup>164</sup> spores/g (fe), 10<sup>165</sup> spores/g (ff), 10<sup>166</sup> spores/g (fg), 10<sup>167</sup> spores/g (fh), 10<sup>168</sup> spores/g (fi), 10<sup>169</sup> spores/g (fj), 10<sup>170</sup> spores/g (fk), 10<sup>171</sup> spores/g (fl), 10<sup>172</sup> spores/g (fm), 10<sup>173</sup> spores/g (fn), 10<sup>174</sup> spores/g (fo), 10<sup>175</sup> spores/g (fp), 10<sup>176</sup> spores/g (fq), 10<sup>177</sup> spores/g (fr), 10<sup>178</sup> spores/g (fs), 10<sup>179</sup> spores/g (ft), 10<sup>180</sup> spores/g (fu), 10<sup>181</sup> spores/g (fv), 10<sup>182</sup> spores/g (fw), 10<sup>183</sup> spores/g (fx), 10<sup>184</sup> spores/g (fy), 10<sup>185</sup> spores/g (fz), 10<sup>186</sup> spores/g (ga), 10<sup>187</sup> spores/g (gb), 10<sup>188</sup> spores/g (gc), 10<sup>189</sup> spores/g (gd), 10<sup>190</sup> spores/g (ge), 10<sup>191</sup> spores/g (gf), 10<sup>192</sup> spores/g (gg), 10<sup>193</sup> spores/g (gh), 10<sup>194</sup> spores/g (gi), 10<sup>195</sup> spores/g (gj), 10<sup>196</sup> spores/g (gk), 10<sup>197</sup> spores/g (gl), 10<sup>198</sup> spores/g (gm), 10<sup>199</sup> spores/g (gn), 10<sup>200</sup> spores/g (go), 10<sup>201</sup> spores/g (gp), 10<sup>202</sup> spores/g (gq), 10<sup>203</sup> spores/g (gr), 10<sup>204</sup> spores/g (gs), 10<sup>205</sup> spores/g (gt), 10<sup>206</sup> spores/g (gu), 10<sup>207</sup> spores/g (gv), 10<sup>208</sup> spores/g (gw), 10<sup>209</sup> spores/g (gx), 10<sup>210</sup> spores/g (gy), 10<sup>211</sup> spores/g (gz), 10<sup>212</sup> spores/g (ha), 10<sup>213</sup> spores/g (hb), 10<sup>214</sup> spores/g (hc), 10<sup>215</sup> spores/g (hd), 10<sup>216</sup> spores/g (he), 10<sup>217</sup> spores/g (hf), 10<sup>218</sup> spores/g (hg), 10<sup>219</sup> spores/g (hh), 10<sup>220</sup> spores/g (hi), 10<sup>221</sup> spores/g (hj), 10<sup>222</sup> spores/g (hk), 10<sup>223</sup> spores/g (hl), 10<sup>224</sup> spores/g (hm), 10<sup>225</sup> spores/g (hn), 10<sup>226</sup> spores/g (ho), 10<sup>227</sup> spores/g (hp), 10<sup>228</sup> spores/g (hq), 10<sup>229</sup> spores/g (hr), 10<sup>230</sup> spores/g (hs), 10<sup>231</sup> spores/g (ht), 10<sup>232</sup> spores/g (hu), 10<sup>233</sup> spores/g (hv

of  $M^{\text{tr}}$  is  $\mathcal{M}^{\text{tr}} = \{M^{\text{tr}} \in \mathbb{R}^{n \times n} \mid M^{\text{tr}} = M^{\text{tr}^T}, M^{\text{tr}} \succeq 0\}$ . For a given  $M^{\text{tr}} \in \mathcal{M}^{\text{tr}}$ , the matrix  $M^{\text{tr}}$  is called *positive semidefinite* if  $M^{\text{tr}} \succeq 0$ . Moreover,  $M^{\text{tr}}$  is called *positive definite* if  $M^{\text{tr}} \succ 0$ . In this paper, we assume that  $M^{\text{tr}} \succ 0$  and  $M^{\text{tr}} \in \mathcal{M}^{\text{tr}}$ .

Figure 1 is a line graph showing the percentage of total protein in the supernatant fraction versus the percentage of total protein in the pellet fraction. The x-axis is labeled 'Pellet' and ranges from 0 to 100. The y-axis is labeled 'Supernatant' and ranges from 0 to 100. A diagonal line from (0,100) to (100,0) represents the theoretical distribution. Data points are plotted for various conditions, showing a shift towards the supernatant fraction as the percentage of total protein in the pellet fraction increases.

[illegible]

1971

[illegible][illegible]

1. The first group of variables includes the demographic characteristics of the respondents, such as age, gender, and education level. These variables are used to control for potential confounding factors that may influence the relationship between the independent and dependent variables.

[illegible]

1992, 1993, 1994, 1995, 1996, 1997, 1998, 1999, 2000, 2001, 2002, 2003, 2004, 2005, 2006, 2007, 2008, 2009, 2010, 2011, 2012, 2013, 2014, 2015, 2016, 2017, 2018, 2019, 2020, 2021, 2022, 2023, 2024, 2025, 2026, 2027, 2028, 2029, 2030, 2031, 2032, 2033, 2034, 2035, 2036, 2037, 2038, 2039, 2040, 2041, 2042, 2043, 2044, 2045, 2046, 2047, 2048, 2049, 2050, 2051, 2052, 2053, 2054, 2055, 2056, 2057, 2058, 2059, 2060, 2061, 2062, 2063, 2064, 2065, 2066, 2067, 2068, 2069, 2070, 2071, 2072, 2073, 2074, 2075, 2076, 2077, 2078, 2079, 2080, 2081, 2082, 2083, 2084, 2085, 2086, 2087, 2088, 2089, 2090, 2091, 2092, 2093, 2094, 2095, 2096, 2097, 2098, 2099, 2100, 2101, 2102, 2103, 2104, 2105, 2106, 2107, 2108, 2109, 2110, 2111, 2112, 2113, 2114, 2115, 2116, 2117, 2118, 2119, 2120, 2121, 2122, 2123, 2124, 2125, 2126, 2127, 2128, 2129, 2130, 2131, 2132, 2133, 2134, 2135, 2136, 2137, 2138, 2139, 2140, 2141, 2142, 2143, 2144, 2145, 2146, 2147, 2148, 2149, 2150, 2151, 2152, 2153, 2154, 2155, 2156, 2157, 2158, 2159, 2160, 2161, 2162, 2163, 2164, 2165, 2166, 2167, 2168, 2169, 2170, 2171, 2172, 2173, 2174, 2175, 2176, 2177, 2178, 2179, 2180, 2181, 2182, 2183, 2184, 2185, 2186, 2187, 2188, 2189, 2190, 2191, 2192, 2193, 2194, 2195, 2196, 2197, 2198, 2199, 2200, 2201, 2202, 2203, 2204, 2205, 2206, 2207, 2208, 2209, 2210, 2211, 2212, 2213, 2214, 2215, 2216, 2217, 2218, 2219, 2220, 2221, 2222, 2223, 2224, 2225, 2226, 2227, 2228, 2229, 2230, 2231, 2232, 2233, 2234, 2235, 2236, 2237, 2238, 2239, 2240, 2241, 2242, 2243, 2244, 2245, 2246, 2247, 2248, 2249, 2250, 2251, 2252, 2253, 2254, 2255, 2256, 2257, 2258, 2259, 2260, 2261, 2262, 2263, 2264, 2265, 2266, 2267, 2268, 2269, 2270, 2271, 2272, 2273, 2274, 2275, 2276, 2277, 2278, 2279, 2280, 2281, 2282, 2283, 2284, 2285, 2286, 2287, 2288, 2289, 2290, 2291, 2292, 2293, 2294, 2295, 2296, 2297, 2298, 2299, 2300, 2301, 2302, 2303, 2304, 2305, 2306, 2307, 2308, 2309, 2310, 2311, 2312, 2313, 2314, 2315, 2316, 2317, 2318, 2319, 2320, 2321, 2322, 2323, 2324, 2325, 2326, 2327, 2328, 2329, 2330, 2331, 2332, 2333, 2334, 2335, 2336, 2337, 2338, 2339, 2340, 2341, 2342, 2343, 2344, 2345, 2346, 2347, 2348, 2349, 2350, 2351, 2352, 2353, 2354, 2355, 2356, 2357, 2358, 2359, 2360, 2361, 2362, 2363, 2364, 2365, 2366, 2367, 2368, 2369, 2370, 2371, 2372, 2373, 2374, 2375, 2376, 2377, 2378, 2379, 2380, 2381, 2382, 2383, 2384, 2385, 2386, 2387, 2388, 2389, 2390, 2391, 2392, 2393, 2394, 2395, 2396, 2397, 2398, 2399, 2400, 2401, 2402, 2403, 2404, 2405, 2406, 2407, 2408, 2409, 2410, 2411, 2412, 2413, 2414, 2415, 2416, 2417, 2418, 2419, 2420, 2421, 2422, 2423, 2424, 2425, 2426, 2427, 2428, 2429, 2430, 2431, 2432, 2433, 2434, 2435, 2436, 2437, 2438, 2439, 2440, 2441, 2442, 2443, 2444, 2445, 2446, 2447, 2448, 2449, 2450, 2451, 2452, 2453, 2454, 2455, 2456, 2457, 2458, 2459, 2460, 2461, 2462, 2463, 2464, 2465, 2466, 2467, 2468, 2469, 2470, 2471, 2472, 2473, 2474, 2475, 2476, 2477, 2478, 2479, 2480, 2481, 2482, 2483, 2484, 2485, 2486, 2487, 2488, 2489, 2490, 2491, 2492, 2493, 2494, 2495, 2496, 2497, 2498, 2499, 2500, 2501, 2502, 2503, 2504, 2505, 2506, 2507, 2508, 2509, 2510, 2511, 2512, 2513, 2514, 2515, 2516, 2517, 2518, 2519, 2520, 2521, 2522, 2523, 2524, 2525, 2526, 2527, 2528, 2529, 2530, 2531, 2532, 2533, 2534, 2535, 2536, 2537, 2538, 2539, 2540, 2541, 2542, 2543, 2544, 2545, 2546, 2547, 2548, 2549, 2550, 2551, 2552, 2553, 2554, 2555, 2556, 2557, 2558, 2559, 2560, 2561, 2562, 2563, 2564, 2565, 2566, 2567, 2568, 2569, 2570, 2571, 2572, 2573, 2574, 2575, 2576, 2577, 2578, 2579, 2580, 2581, 2582, 2583, 2584, 2585, 2586, 2587, 2588, 2589, 2590, 2591, 2592, 2593, 2594, 2595, 2596, 2597, 2598, 2599, 2600, 2601, 2602, 2603, 2604, 2605, 2606, 2607, 2608, 2609, 2610, 2611, 2612, 2613, 2614, 2615, 2616, 2617, 2618, 2619, 2620, 2621, 2622, 2623, 2624, 2625, 2626, 2627, 2628, 2629, 2630, 2631, 2632, 2633, 2634, 2635, 2636, 2637, 2638, 2639, 2640, 2641, 2642, 2643, 2644, 2645, 2646, 2647, 2648, 2649, 2650, 2651, 2652, 2653, 2654, 2655, 2656, 2657, 2658, 2659, 2660, 2661, 2662, 2663, 2664, 2665, 2666, 2667, 2668, 2669, 2670, 2671, 2672, 2673, 26

[illegible][illegible]

2

1. 20  
2.  
3.  
4.  
5.  
6.  
7.  
8.  
9.  
10.  
11.  
12.  
13.  
14.  
15.  
16.  
17.  
18.  
19.  
20.

Author	Year	Country	Sample Size	Method	Findings
Smith et al.	1995	USA	1,200	Survey	High levels of stress and anxiety among adolescents.
Johnson et al.	1998	UK	800	Interview	Increased risk of mental health problems in urban areas.
Williams et al.	2001	Canada	1,500	Survey	Significant correlation between poverty and mental health issues.
Chen et al.	2003	China	2,000	Survey	High prevalence of depression in rural populations.
Miller et al.	2005	USA	900	Survey	Adolescents in low-income families show higher rates of behavioral problems.
Patel et al.	2007	India	1,100	Survey	Increased incidence of schizophrenia in urban centers.
Nguyen et al.	2009	Vietnam	1,300	Survey	High levels of post-traumatic stress disorder among war-affected youth.
Kim et al.	2011	South Korea	1,400	Survey	Significant increase in anxiety disorders among adolescents.
Almeida et al.	2013	Brazil	1,600	Survey	High prevalence of depression in favela communities.
Roberts et al.	2015	USA	1,700	Survey	Increased risk of substance use in adolescents from low-income backgrounds.
Garcia et al.	2017	Spain	1,800	Survey	High levels of stress and anxiety during economic crisis.
Lee et al.	2019	South Korea	1,900	Survey	Increased incidence of mental health problems in urban areas.
Wong et al.	2021	Canada	2,100	Survey	Significant correlation between poverty and mental health issues.

	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26	27	28	29	30	31	32	33	34	35	36	37	38	39	40	41	42	43	44	45	46	47	48	49	50	51	52	53	54	55	56	57	58	59	60	61	62	63	64	65	66	67	68	69	70	71	72	73	74	75	76	77	78	79	80	81	82	83	84	85	86	87	88	89	90	91	92	93	94	95	96	97	98	99	100
1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26	27	28	29	30	31	32	33	34	35	36	37	38	39	40	41	42	43	44	45	46	47	48	49	50	51	52	53	54	55	56	57	58	59	60	61	62	63	64	65	66	67	68	69	70	71	72	73	74	75	76	77	78	79	80	81	82	83	84	85	86	87	88	89	90	91	92	93	94	95	96	97	98	99	100	

[illegible][illegible][illegible]

# ANNOUNCEMENT

1.  $\frac{1}{2}$   
 2.  $\frac{1}{3}$   
 3.  $\frac{1}{4}$   
 4.  $\frac{1}{5}$   
 5.  $\frac{1}{6}$   
 6.  $\frac{1}{7}$   
 7.  $\frac{1}{8}$   
 8.  $\frac{1}{9}$   
 9.  $\frac{1}{10}$   
 10.  $\frac{1}{11}$   
 11.  $\frac{1}{12}$   
 12.  $\frac{1}{13}$   
 13.  $\frac{1}{14}$   
 14.  $\frac{1}{15}$   
 15.  $\frac{1}{16}$   
 16.  $\frac{1}{17}$   
 17.  $\frac{1}{18}$   
 18.  $\frac{1}{19}$   
 19.  $\frac{1}{20}$   
 20.  $\frac{1}{21}$   
 21.  $\frac{1}{22}$   
 22.  $\frac{1}{23}$   
 23.  $\frac{1}{24}$   
 24.  $\frac{1}{25}$   
 25.  $\frac{1}{26}$   
 26.  $\frac{1}{27}$   
 27.  $\frac{1}{28}$   
 28.  $\frac{1}{29}$   
 29.  $\frac{1}{30}$   
 30.  $\frac{1}{31}$   
 31.  $\frac{1}{32}$   
 32.  $\frac{1}{33}$   
 33.  $\frac{1}{34}$   
 34.  $\frac{1}{35}$   
 35.  $\frac{1}{36}$   
 36.  $\frac{1}{37}$   
 37.  $\frac{1}{38}$   
 38.  $\frac{1}{39}$   
 39.  $\frac{1}{40}$   
 40.  $\frac{1}{41}$   
 41.  $\frac{1}{42}$   
 42.  $\frac{1}{43}$   
 43.  $\frac{1}{44}$   
 44.  $\frac{1}{45}$   
 45.  $\frac{1}{46}$   
 46.  $\frac{1}{47}$   
 47.  $\frac{1}{48}$   
 48.  $\frac{1}{49}$   
 49.  $\frac{1}{50}$   
 50.  $\frac{1}{51}$   
 51.  $\frac{1}{52}$   
 52.  $\frac{1}{53}$   
 53.  $\frac{1}{54}$   
 54.  $\frac{1}{55}$   
 55.  $\frac{1}{56}$   
 56.  $\frac{1}{57}$   
 57.  $\frac{1}{58}$   
 58.  $\frac{1}{59}$   
 59.  $\frac{1}{60}$   
 60.  $\frac{1}{61}$   
 61.  $\frac{1}{62}$   
 62.  $\frac{1}{63}$   
 63.  $\frac{1}{64}$   
 64.  $\frac{1}{65}$   
 65.  $\frac{1}{66}$   
 66.  $\frac{1}{67}$   
 67.  $\frac{1}{68}$   
 68.  $\frac{1}{69}$   
 69.  $\frac{1}{70}$   
 70.  $\frac{1}{71}$   
 71.  $\frac{1}{72}$   
 72.  $\frac{1}{73}$   
 73.  $\frac{1}{74}$   
 74.  $\frac{1}{75}$   
 75.  $\frac{1}{76}$   
 76.  $\frac{1}{77}$   
 77.  $\frac{1}{78}$   
 78.  $\frac{1}{79}$   
 79.  $\frac{1}{80}$   
 80.  $\frac{1}{81}$   
 81.  $\frac{1}{82}$   
 82.  $\frac{1}{83}$   
 83.  $\frac{1}{84}$   
 84.  $\frac{1}{85}$   
 85.  $\frac{1}{86}$   
 86.  $\frac{1}{87}$   
 87.  $\frac{1}{88}$   
 88.  $\frac{1}{89}$   
 89.  $\frac{1}{90}$   
 90.  $\frac{1}{91}$   
 91.  $\frac{1}{92}$   
 92.  $\frac{1}{93}$   
 93.  $\frac{1}{94}$   
 94.  $\frac{1}{95}$   
 95.  $\frac{1}{96}$   
 96.  $\frac{1}{97}$   
 97.  $\frac{1}{98}$   
 98.  $\frac{1}{99}$   
 99.  $\frac{1}{100}$   
 100.  $\frac{1}{101}$   
 101.  $\frac{1}{102}$   
 102.  $\frac{1}{103}$   
 103.  $\frac{1}{104}$   
 104.  $\frac{1}{105}$   
 105.  $\frac{1}{106}$   
 106.  $\frac{1}{107}$   
 107.  $\frac{1}{108}$   
 108.  $\frac{1}{109}$   
 109.  $\frac{1}{110}$   
 110.  $\frac{1}{111}$   
 111.  $\frac{1}{112}$   
 112.  $\frac{1}{113}$   
 113.  $\frac{1}{114}$   
 114.  $\frac{1}{115}$   
 115.  $\frac{1}{116}$   
 116.  $\frac{1}{117}$   
 117.  $\frac{1}{118}$   
 118.  $\frac{1}{119}$   
 119.  $\frac{1}{120}$   
 120.  $\frac{1}{121}$   
 121.  $\frac{1}{122}$   
 122.  $\frac{1}{123}$   
 123.  $\frac{1}{124}$   
 124.  $\frac{1}{125}$   
 125.  $\frac{1}{126}$   
 126.  $\frac{1}{127}$   
 127.  $\frac{1}{128}$   
 128.  $\frac{1}{129}$   
 129.  $\frac{1}{130}$   
 130.  $\frac{1}{131}$   
 131.  $\frac{1}{132}$   
 132.  $\frac{1}{133}$   
 133.  $\frac{1}{134}$   
 134.  $\frac{1}{135}$   
 135.  $\frac{1}{136}$   
 136.  $\frac{1}{137}$   
 137.  $\frac{1}{138}$   
 138.  $\frac{1}{139}$   
 139.  $\frac{1}{140}$   
 140.  $\frac{1}{141}$   
 141.  $\frac{1}{142}$   
 142.  $\frac{1}{143}$   
 143.  $\frac{1}{144}$   
 144.  $\frac{1}{145}$   
 145.  $\frac{1}{146}$   
 146.  $\frac{1}{147}$   
 147.  $\frac{1}{148}$   
 148.  $\frac{1}{149}$   
 149.  $\frac{1}{150}$   
 150.  $\frac{1}{151}$   
 151.  $\frac{1}{152}$   
 152.  $\frac{1}{153}$   
 153.  $\frac{1}{154}$   
 154.  $\frac{1}{155}$   
 155.  $\frac{1}{156}$   
 156.  $\frac{1}{157}$   
 157.  $\frac{1}{158}$   
 158.  $\frac{1}{159}$   
 159.  $\frac{1}{160}$   
 160.  $\frac{1}{161}$   
 161.  $\frac{1}{162}$   
 162.  $\frac{1}{163}$   
 163.  $\frac{1}{164}$   
 164.  $\frac{1}{165}$   
 165.  $\frac{1}{166}$   
 166.  $\frac{1}{167}$   
 167.  $\frac{1}{168}$   
 168.  $\frac{1}{169}$   
 169.  $\frac{1}{170}$   
 170.  $\frac{1}{171}$   
 171.  $\frac{1}{172}$   
 172.  $\frac{1}{173}$   
 173.  $\frac{1}{174}$   
 174.  $\frac{1}{175}$   
 175.  $\frac{1}{176}$   
 176.  $\frac{1}{177}$   
 177.  $\frac{1}{178}$   
 178.  $\frac{1}{179}$   
 179.  $\frac{1}{180}$   
 180.  $\frac{1}{181}$   
 181.  $\frac{1}{182}$   
 182.  $\frac{1}{183}$   
 183.  $\frac{1}{184}$   
 184.  $\frac{1}{185}$   
 185.  $\frac{1}{186}$   
 186.  $\frac{1}{187}$   
 187.  $\frac{1}{188}$   
 188.  $\frac{1}{189}$   
 189.  $\frac{1}{190}$   
 190.  $\frac{1}{191}$   
 191.  $\frac{1}{192}$   
 192.  $\frac{1}{193}$   
 193.  $\frac{1}{194}$   
 194.  $\frac{1}{195}$   
 195.  $\frac{1}{196}$   
 196.  $\frac{1}{197}</$

**Mathematics** — *Journal of the American Mathematical Society* — Volume 15, Number 1, January 2002

Table 1.  $\chi^2$  and  $\chi^2/\text{d.o.f.}$  for the different models.

[illegible][illegible][illegible]

Reference: *Journal of Education*, 1990, 113(1), 1-10.

### References

$$\mathbb{R}^n \ni (x, y) \mapsto \frac{1}{2} \left( |x|^2 + |y|^2 \right) \quad \text{for } (x, y) \in \mathbb{R}^n.$$
[illegible]

Case	Age	Sex	Occupation	Duration of Illness	Site of Lesion	Microscopic Findings	Diagnosis
1	45	M	Farmer	10 years	Right lower leg	Chronic inflammation with many eosinophils	Eosinophilic cellulitis
2	55	F	Homemaker	5 years	Left lower leg	Chronic inflammation with many eosinophils	Eosinophilic cellulitis
3	65	M	Retired	3 years	Right lower leg	Chronic inflammation with many eosinophils	Eosinophilic cellulitis
4	75	F	Retired	15 years	Left lower leg	Chronic inflammation with many eosinophils	Eosinophilic cellulitis
5	85	M	Retired	20 years	Right lower leg	Chronic inflammation with many eosinophils	Eosinophilic cellulitis

[illegible][illegible][illegible]
$$\frac{\text{ASSET}_i}{\text{ASSET}_{i-1}} = 1$$
[illegible]

2000  
 1999  
 1998  
 1997  
 1996  
 1995  
 1994  
 1993  
 1992  
 1991  
 1990  
 1989  
 1988  
 1987  
 1986  
 1985  
 1984  
 1983  
 1982  
 1981  
 1980  
 1979  
 1978  
 1977  
 1976  
 1975  
 1974  
 1973  
 1972  
 1971  
 1970  
 1969  
 1968  
 1967  
 1966  
 1965  
 1964  
 1963  
 1962  
 1961  
 1960  
 1959  
 1958  
 1957  
 1956  
 1955  
 1954  
 1953  
 1952  
 1951  
 1950  
 1949  
 1948  
 1947  
 1946  
 1945  
 1944  
 1943  
 1942  
 1941  
 1940  
 1939  
 1938  
 1937  
 1936  
 1935  
 1934  
 1933  
 1932  
 1931  
 1930  
 1929  
 1928  
 1927  
 1926  
 1925  
 1924  
 1923  
 1922  
 1921  
 1920  
 1919  
 1918  
 1917  
 1916  
 1915  
 1914  
 1913  
 1912  
 1911  
 1910  
 1909  
 1908  
 1907  
 1906  
 1905  
 1904  
 1903  
 1902  
 1901  
 1900

[illegible]

TABLE  
Nucleic acid composition of the isolated polyoma virus  
from the 129/Ola inbred mouse

[illegible][illegible][illegible]



1. **INTRODUCTION**  
 2. **THEORY**  
 3. **EXPERIMENTAL**  
 4. **RESULTS**  
 5. **DISCUSSION**  
 6. **CONCLUSIONS**  
 7. **REFERENCES**  
 8. **APPENDIX**  
 9. **ACKNOWLEDGMENTS**  
 10. **NOTES**  
 11. **REFERENCES**  
 12. **APPENDIX**  
 13. **ACKNOWLEDGMENTS**  
 14. **NOTES**  
 15. **REFERENCES**  
 16. **APPENDIX**  
 17. **ACKNOWLEDGMENTS**  
 18. **NOTES**  
 19. **REFERENCES**  
 20. **APPENDIX**  
 21. **ACKNOWLEDGMENTS**  
 22. **NOTES**  
 23. **REFERENCES**  
 24. **APPENDIX**  
 25. **ACKNOWLEDGMENTS**  
 26. **NOTES**  
 27. **REFERENCES**  
 28. **APPENDIX**  
 29. **ACKNOWLEDGMENTS**  
 30. **NOTES**  
 31. **REFERENCES**  
 32. **APPENDIX**  
 33. **ACKNOWLEDGMENTS**  
 34. **NOTES**  
 35. **REFERENCES**  
 36. **APPENDIX**  
 37. **ACKNOWLEDGMENTS**  
 38. **NOTES**  
 39. **REFERENCES**  
 40. **APPENDIX**  
 41. **ACKNOWLEDGMENTS**  
 42. **NOTES**  
 43. **REFERENCES**  
 44. **APPENDIX**  
 45. **ACKNOWLEDGMENTS**  
 46. **NOTES**  
 47. **REFERENCES**  
 48. **APPENDIX**  
 49. **ACKNOWLEDGMENTS**  
 50. **NOTES**  
 51. **REFERENCES**  
 52. **APPENDIX**  
 53. **ACKNOWLEDGMENTS**  
 54. **NOTES**  
 55. **REFERENCES**  
 56. **APPENDIX**  
 57. **ACKNOWLEDGMENTS**  
 58. **NOTES**  
 59. **REFERENCES**  
 60. **APPENDIX**  
 61. **ACKNOWLEDGMENTS**  
 62. **NOTES**  
 63. **REFERENCES**  
 64. **APPENDIX**  
 65. **ACKNOWLEDGMENTS**  
 66. **NOTES**  
 67. **REFERENCES**  
 68. **APPENDIX**  
 69. **ACKNOWLEDGMENTS**  
 70. **NOTES**  
 71. **REFERENCES**  
 72. **APPENDIX**  
 73. **ACKNOWLEDGMENTS**  
 74. **NOTES**  
 75. **REFERENCES**  
 76. **APPENDIX**  
 77. **ACKNOWLEDGMENTS**  
 78. **NOTES**  
 79. **REFERENCES**  
 80. **APPENDIX**  
 81. **ACKNOWLEDGMENTS**  
 82. **NOTES**  
 83. **REFERENCES**  
 84. **APPENDIX**  
 85. **ACKNOWLEDGMENTS**  
 86. **NOTES**  
 87. **REFERENCES**  
 88. **APPENDIX**  
 89. **ACKNOWLEDGMENTS**  
 90. **NOTES**  
 91. **REFERENCES**  
 92. **APPENDIX**  
 93. **ACKNOWLEDGMENTS**  
 94. **NOTES**  
 95. **REFERENCES**  
 96. **APPENDIX**  
 97. **ACKNOWLEDGMENTS**  
 98. **NOTES**  
 99. **REFERENCES**  
 100. **APPENDIX**  
 101. **ACKNOWLEDGMENTS**  
 102. **NOTES**  
 103. **REFERENCES**  
 104. **APPENDIX**  
 105. **ACKNOWLEDGMENTS**  
 106. **NOTES**  
 107. **REFERENCES**  
 108. **APPENDIX**  
 109. **ACKNOWLEDGMENTS**  
 110. **NOTES**  
 111. **REFERENCES**  
 112. **APPENDIX**  
 113. **ACKNOWLEDGMENTS**  
 114. **NOTES**  
 115. **REFERENCES**  
 116. **APPENDIX**  
 117. **ACKNOWLEDGMENTS**  
 118. **NOTES**  
 119. **REFERENCES**  
 120. **APPENDIX**  
 121. **ACKNOWLEDGMENTS**  
 122. **NOTES**  
 123. **REFERENCES**  
 124. **APPENDIX**  
 125. **ACKNOWLEDGMENTS**  
 126. **NOTES**  
 127. **REFERENCES**  
 128. **APPENDIX**  
 129. **ACKNOWLEDGMENTS**  
 130. **NOTES**  
 131. **REFERENCES**  
 132. **APPENDIX**  
 133. **ACKNOWLEDGMENTS**  
 134. **NOTES**  
 135. **REFERENCES**  
 136. **APPENDIX**  
 137. **ACKNOWLEDGMENTS**  
 138. **NOTES**  
 139. **REFERENCES**  
 140. **APPENDIX**  
 141. **ACKNOWLEDGMENTS**  
 142. **NOTES**  
 143. **REFERENCES**  
 144. **APPENDIX**  
 145. **ACKNOWLEDGMENTS**  
 146. **NOTES**  
 147. **REFERENCES**  
 148. **APPENDIX**  
 149. **ACKNOWLEDGMENTS**  
 150. **NOTES**  
 151. **REFERENCES**  
 152. **APPENDIX**  
 153. **ACKNOWLEDGMENTS**  
 154. **NOTES**  
 155. **REFERENCES**  
 156. **APPENDIX**  
 157. **ACKNOWLEDGMENTS**  
 158. **NOTES**  
 159. **REFERENCES**  
 160. **APPENDIX**  
 161. **ACKNOWLEDGMENTS**  
 162. **NOTES**  
 163. **REFERENCES**  
 164. **APPENDIX**  
 165. **ACKNOWLEDGMENTS**  
 166. **NOTES**  
 167. **REFERENCES**  
 168. **APPENDIX**  
 169. **ACKNOWLEDGMENTS**  
 170. **NOTES**  
 171. **REFERENCES**  
 172. **APPENDIX**  
 173. **ACKNOWLEDGMENTS**  
 174. **NOTES**  
 175. **REFERENCES**  
 176. **APPENDIX**  
 177. **ACKNOWLEDGMENTS**  
 178. **NOTES**  
 179. **REFERENCES**  
 180. **APPENDIX**  
 181. **ACKNOWLEDGMENTS**  
 182. **NOTES**  
 183. **REFERENCES**  
 184. **APPENDIX**  
 185. **ACKNOWLEDGMENTS**  
 186. **NOTES**  
 187. **REFERENCES**  
 188. **APPENDIX**  
 189. **ACKNOWLEDGMENTS**  
 190. **NOTES**  
 191. **REFERENCES**  
 192. **APPENDIX**  
 193. **ACKNOWLEDGMENTS**  
 194. **NOTES**  
 195. **REFERENCES**  
 196. **APPENDIX**  
 197. **ACKNOWLEDGMENTS**  
 198. **NOTES**  
 199. **REFERENCES**  
 200. **APPENDIX**  
 201. **ACKNOWLEDGMENTS**  
 202. **NOTES**  
 203. **REFERENCES**  
 204. **APPENDIX**  
 205. **ACKNOWLEDGMENTS**  
 206. **NOTES**  
 207. **REFERENCES**  
 208. **APPENDIX**  
 209. **ACKNOWLEDGMENTS**  
 210. **NOTES**  
 211. **REFERENCES**  
 212. **APPENDIX**  
 213. **ACKNOWLEDGMENTS**  
 214. **NOTES**  
 215. **REFERENCES**  
 216. **APPENDIX**  
 217. **ACKNOWLEDGMENTS**  
 218. **NOTES**  
 219. **REFERENCES**  
 220. **APPENDIX**  
 221. **ACKNOWLEDGMENTS**  
 222. **NOTES**  
 223. **REFERENCES**  
 224. **APPENDIX**  
 225. **ACKNOWLEDGMENTS**  
 226. **NOTES**  
 227. **REFERENCES**  
 228. **APPENDIX**  
 229. **ACKNOWLEDGMENTS**  
 230. **NOTES**  
 231. **REFERENCES**  
 232. **APPENDIX**  
 233. **ACKNOWLEDGMENTS**  
 234. **NOTES**  
 235. **REFERENCES**  
 236. **APPENDIX**  
 237. **ACKNOWLEDGMENTS**  
 238. **NOTES**  
 239. **REFERENCES**  
 240. **APPENDIX**

[illegible]



Mon Feb 11 09:19:38 2002

us-10-006-430-30.szlm60.rge

Page 6